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ABSTRACT 
Copper is a vital micronutrient that impacts a variety of essential biochemical pathways within 
mammalian cells. Yet little is known about the homeostatic mechanisms that maintain intracellular 
copper levels or their relative importance across cell types. Recent evidence argues that copper 
handling pathways contained within the mitochondrion play an active role in the regulation of cellular 
copper homeostasis, as human patients with pathogenic mutations in the mitochondrial copper 
chaperone SCO1 exhibit tissue-specific deficits that are attributable in part to a severe copper 
deficiency. However, how the activity of mitochondrial copper handling pathways is functionally 
coupled to other cellular copper handling machinery and how this coupling impinges upon cellular 
copper sensing in general remains ill-defined. Developing an understanding of how the organelle is 
integrated into the functional framework that regulates copper homeostasis may be further challenged 
by the fact SCO1 patients from three unique pedigrees present with drastically different, tissue-
specific clinical phenotypes, suggesting that mitochondrial signalling through SCO1 to regulate 
copper homeostasis may exhibit cell type-specific features. To begin investigating these questions, 
we generated and characterized multiple transgenic Sco1 models of human disease in which SCO1 
function is perturbed in the heart and liver, two of the most affected tissues in SCO1 patients. Deletion 
of Sco1 in the liver was lethal and mice presented with a significant hepatopathy and hepatic steatosis. 
Sco1 null hepatocytes had both an isolated COX deficiency as well as a severe copper deficiency, the 
latter of which was attributable to an increase in the degradation of the high-affinity copper transporter 
CTR1. Deletion of Sco1 in the heart or striated muscle was also lethal with mice developing a dilated 
cardiomyopathy. Similar to the Sco1 null livers, Sco1 null hearts displayed a combined COX and 
copper deficiency; however, in the case of the Sco1 null hearts, the copper deficiency was caused by 
the relocalization of CTR1 to intracellular vesicles rather than its degradation. To further examine the 
human condition, we also generated Sco1 knock-in mice harbouring a G115S substitution, which in 
patients causes a fatal infantile hypertrophic cardiomyopathy. The heart of this knock-in mouse 
phenocopied the Sco1 knockout heart, suggesting that both the null and knock-in models afforded one 
with the opportunity to investigate the underlying etiology of the associated human diseases. 
Collectively, my Ph.D. thesis data confirm that SCO1 fulfills an evolutionarily conserved role in 
maintaining cellular copper homeostasis and identify a novel role for the protein in regulating the 
function of the copper import machinery.  
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1.0 INTRODUCTION 
1.1 Copper in the human body 
1.1.1 Physiological roles of copper within the cell 
Copper is an essential dietary micronutrient required by all five kingdoms of life. The 
essentiality of copper comes from its ability to rapidly switch between two redox states, from Cu+1 to 
Cu+2, which allows the metal ion to accept and donate electrons and therefore contribute to oxidation-
reduction reactions. Cells exploit this ability, utilizing copper as a structural or catalytic cofactor in 
enzymes which catalyze a multitude of reactions involved in maintaining cellular homeostasis (Kim 
et al., 2008). In humans, multiple, well-characterized cuproenzymes exist including cytochrome c 
oxidase (electron transport chain complex) (Timón-Gómez et al., 2017), superoxide dismutase 
(removal of toxic free radicals) (Robinson and Winge, 2010), dopamine -hydroylase (norepinephrine 
biosynthetic pathway) (Lutsenko et al., 2010), lysyl oxidase (collagen crosslinking) (Finney et al., 
2014), tyrosinase (pigment formation) (Ramsden and Riley, 2014), as well as multiple enzymes 
involved in maintaining proper iron homeostasis (ceruloplasmin, hephaestin, zyklopen) (Vashchenko 
and MacGillivray, 2013). Copper also fulfills other, more direct roles within the cell and is crucial to 
innate immunity (Festa and Thiele, 2012), oncogenesis (Brady et al., 2014), and signal transduction 
(Krishnamoorthy et al., 2016), all of which are relatively new and prominent topics in the field. 
Despite the fact copper is essential for proper cell growth and function, it is toxic in excess. 
Excess, or mishandled, copper can potentiate the production of dangerous oxidative molecules 
through Haber-Weiss and Fenton-like reactions (Figure 1.1). These oxidative molecules, which 
include superoxide or hydrogen peroxide, are highly reactive and can induce oxidative damage to 
nucleic acids, proteins and lipids thereby disrupting cellular functions (Stohs and Bagchi, 1995). 
Although elevated free radical generation is still a prevalent issue in copper overloaded cells (Jomova 
and Valko, 2011), recent studies suggest that the primary cause of copper toxicity reflects its ability 
to displace iron from iron-sulphur cluster containing proteins leading to their inactivation (Brancaccio 
et al., 2017; Macomber and Imlay, 2009). Iron-sulphur clusters are key catalytic co-factors for several 
proteins with critical roles in cellular homeostasis and their loss of function is extremely detrimental 
to cell viability (Lill, 2009). These two sides of copper, how it is essential for life but toxic in excess, 
make the homeostatic regulation of the metal ion important. The mechanisms involved in maintaining 
copper homeostasis are therefore discussed below. 
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Figure 1.1: Free radical generation through the Harber-Weiss Reaction 
By switching between two redox states (Cu2+ and Cu+) copper can catalyze the generation of free 
radicals, such as the hydroxyl radical shown here, through Fenton and Harber-Weiss reactions.  
 
1.1.2 Import and export of copper across the plasma membrane 
The most logical place to begin the discussion of copper homeostasis is import of the metal ion 
into the cell. Copper uptake into the eukaryotic cell is mediated predominantly by the evolutionarily 
conserved protein CTR1, the only known high affinity copper importer in mammals (Dancis et al., 
1994; Zhou and Gitschier, 1997). Although other, low affinity mechanisms exist for copper import 
(Kidane et al., 2012; Lee et al., 2002), they are ill-defined and unable to fully compensate for loss of 
CTR1 function as Ctr1 deletion in the mouse is embryonic lethal (Lee et al., 2001). CTR1 functions 
as a homotrimer, with each monomer consisting of a 190-amino acid protein with 3 transmembrane 
regions (Figure 1.2) (Lee et al., 2002). These monomers interact through their extracellular N-termini, 
effectively forming a pore to facilitate copper transport across the plasma membrane (Aller and Unger, 
2006; De Feo et al., 2009; Klomp et al., 2003; Schushan et al., 2010). Functional characterization of 
CTR1 deletion mutants in yeast and mammalian cells identified a conserved Mx3M motif within the 
second transmembrane domain which is not involved in localizing the protein to the plasma membrane 
but is essential for copper transport (Guo et al., 2004; Puig et al., 2002). It is thought that this Mx3M 
motif functions as a copper-binding site, with the methionine residues acting as soft Lewis bases to 
facilitate copper transport across the membrane. Although not essential, other N-terminal extracellular 
motifs have also been shown to influence the kinetics of copper transport. Deletion of one of the two 
conserved MxxMxM motifs in CTR1 does not completely abolish copper transport but prevents it 
from rescuing the growth defect of a ctr1 yeast strain under copper-depleted conditions, suggesting 
this motif has a role in high affinity uptake (Puig et al., 2002). 
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Figure 1.2: Topology of human CTR1 
(A) Diagram of a topological model of human CTR1 (hCTR1). Critical motifs discussed in text are 
noted in boxes. hCTR1 has 3 transmembrane domains (TM1-3), the second of which contains the 
Mx3M motif which is critical for binding copper and allowing import across the membrane. The N-
terminus of hCTR1 contains histidine (H) and methionine (M) rich regions, and the two MxMxxM 
motifs that are critical for binding copper and allowing for high-affinity import of the ion.  The C-
terminal HCH motif is involved in the regulation of copper import. There are two glycosylation events 
at the N-terminal region of the protein, at N15 and T27, noted with black branches. (B) A model of 
the pore formed by hCTR1 trimer that facilitates copper transport, as determined by cryo-electron 
microscopy. (Figure adapted from Schushan et al., 2010.) 
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Under conditions of copper excess, CTR1 is removed from the plasma membrane to limit a 
further increase in intracellular copper concentrations (Petris et al., 2003). This copper-mediated 
endocytosis of CTR1 is dependent on copper transport, as the Mx3M mutant is constitutively localized 
to the plasma membrane independent of the extracellular copper concentration (Guo et al., 2004). 
Similarly, the localization of the MxxMxM mutant is unresponsive to mild copper excess (Puig et al., 
2002). These data collectively suggest that cellular copper sensing does not occur extracellularly and 
that the critical residues of CTR1 involved in stimulating copper-mediated endocytosis are localized 
on the cytosolic face of the plasma membrane. Consistent with this idea, deletion of the copper-
binding intracellular HCH motif has been shown to abolish copper-mediated endocytosis while 
increasing copper transport activity (Maryon et al., 2013a). In fact, deletion and point mutants of this 
HCH motif are highly sensitive to increases in extracellular copper concentrations suggesting that 
these residues are critical for the regulation of copper homeostasis (Maryon et al., 2013a). Under 
prolonged conditions of copper excess, endocytosed CTR1 is degraded (Petris et al., 2003) or 
maintained within the cytosol on recycling endosomes to allow for its eventual return to the plasma 
membrane upon normalization of intracellular copper concentrations (Clifford et al., 2016; Molloy 
and Kaplan, 2009). Despite the fact copper driven endocytosis of CTR1 is a well-characterized 
phenomenon, little is known about the associated regulatory mechanisms or the cell-type specific 
differences in inputs that determine whether internalized CTR1 is degraded or trafficked within 
recycling endosomes. 
Like many other plasma membrane transporters, CTR1 function is heavily influenced by several 
post-translational modifications (PTMs). The first PTM during its maturation is an N-linked 
glycosylation event at the Asn15 residue, which shifts the apparent molecular weight of CTR1 from 
21 kDa to ~30 kDa.  Although this glycosylation step is conserved in mammals, mutating the 
conserved asparagine does not affect the trafficking of the protein to the plasma membrane or high-
affinity copper import (Klomp et al., 2002; Maryon et al., 2007). The second PTM is an O-linked 
glycosylation event at Thr27 which induces a more modest ∼2 kDa shift in the apparent molecular 
weight of CTR1 (Maryon et al., 2007). Glycosylation at this residue has been shown to protect the N-
terminal ectodomain of CTR1 from targeted proteolytic cleavage, which results in a truncated version 
of the protein of ∼17 kDa (Maryon et al., 2007, 2009). The exact location of this cleavage site in 
human CTR1 was first reported to be between residues 29–33 (ASHSH), based primarily on the 
different in-gel migration pattern of relevant point mutants (Maryon et al., 2009). Recently, however, 
liquid chromatography-mass spectrometry (LC-MS) analysis of both the human and murine forms of 
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truncated CTR1 identified multiple cleavage events within the ectodomain at the methionine residues 
at positions 40, 41, 42, and 45 (Öhrvik et al., 2013). The truncated version of CTR1 traffics primarily 
to late endosomes with a lower rate of copper transport (Maryon et al., 2007) and its endosomal 
localization depends on the homologous CTR2 protein, which functions to recruit the full-length 
CTR1 protein to the protease cathepsin L to promote its cleavage (Öhrvik et al., 2013). Notably, 
copper accumulates in punctate structures within both the brains of mice lacking CTR2 and Ctr2 
knockout MEFs, both of which lack the truncated form of CTR1. This has led to the suggestion that 
the truncated form of CTR1 may play a role in releasing endosomal copper stores (Öhrvik et al., 2013; 
Öhrvik et al., 2016).  
The P-type ATPases ATP7A and ATP7B are involved in both the metallation of secreted 
cuproproteins and copper export from the cell. Mutations in ATP7A and ATP7B disrupt protein 
function and cause Menkes and Wilson disease respectively, fatal clinical conditions in which patients 
experience marked tissue-specific perturbations in copper homeostasis (Chelly et al., 1993; Mercer et 
al., 1993; Petrukhin et al., 1994; Vulpe et al., 1993). ATP7A and ATP7B are integral membrane 
proteins of 180 and 160 kDa and share significant sequence identity, each having eight transmembrane 
domains and 6 cytosolic N-terminal, metal-binding domains containing conserved MxCxxC motifs 
(Lutsenko et al., 2007). Both P-type ATPases localize primarily to the trans-Golgi network (TGN), 
where they serve to transport copper across the lumen of the Golgi for the metallation of secreted 
cupro-proteins like ceruloplasmin (Schaefer et al., 1999; Yamaguchi et al., 1996). Their ability to 
transport copper involves initial binding of the metal ion by a CPC motif and active coupling of ATP 
hydrolysis within the ATP binding domain to create a phosphorylated intermediate. This 
phosphorylation event induces a conformational change in the protein that then enables the release of 
the copper ion on the obverse side of the membrane (Petris et al., 2002). 
Despite their high degree of homology, ATP7A and ATP7B fulfill unique functions within 
mammals. Both proteins exhibit opposing localization patterns (apical vs. basolateral) during copper-
stimulated trafficking in polarized epithelial cells (Braiterman et al., 2009; Greenough, 2004). ATP7B 
also exhibits a restricted expression profile relative to ATP7A, and is most readily detectable in the 
liver, kidney, brain, epithelial cells and eyes (Wang et al., 2011). One of the most widely recognized 
and well-characterized functions of ATP7B is the export of excess copper into the bile. Under 
conditions of hepatic copper excess, the localization of ATP7B in hepatocytes shifts from the TGN to 
the apical canalicular membrane (Yamaguchi et al., 1996), an event that requires a highly conserved 
stretch of 9 amino acids (Braiterman et al., 2009). Near the canalicular membrane, ATP7B interacts 
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with lysosomes, pumping excess copper into the lysosomal lumen (Polishchuk et al., 2014). These 
lysosomes then undergo exocytosis from the canalicular membrane thereby releasing copper into bile 
for its subsequent excretion from the body in the feces (Polishchuk et al., 2014).  
ATP7A is more widely expressed across tissues than ATP7B, and is therefore responsible for 
metallating the majority of secreted proteins within the body (Wang et al., 2011). ATP7A also 
functions to pump copper across membranes to supply it to peripheral tissues. This is perhaps best 
illustrated by the intestinal enterocyte, which utilizes apically localized CTR1 to absorb dietary copper 
and basally localized ATP7A to promote its subsequent release into the portal circulation (Nevitt et 
al., 2012). However, ATP7A is also involved in copper transport across the blood-cerebrospinal fluid 
barrier into the cerebrospinal fluid and copper export from the kidneys. Therefore, mutations that 
affect ATP7A function cause severe changes in the physiological concentrations of copper in the brain 
and kidney (Yoshimura et al., 1995) as well as the intestinal enterocyte (Danks et al., 1973). To 
facilitate copper transport under both normal and excess copper conditions, a percentage of the total 
pool of ATP7A protein re-localizes from the TGN to the plasma membrane and cytoplasmic vesicles 
(Petris et al., 1996, 2002). Dynamic ATP7A trafficking depends on its ability to transport copper, and 
point mutations that compromise this property abolish its regulated redistribution to the cellular 
periphery (Petris et al., 2002; Voskoboinik et al., 2003). Additional structure-function studies 
established that at least one of the 5th or 6th N-terminal metal binding sites is required for ATP7A 
trafficking to the plasma membrane (Strausak et al., 1999), and a C-terminal di-leucine motif is 
essential for TGN recycling (Petris and Mercer, 1999). Although a change in ATP7A localization to 
the cellular periphery is required for copper export, whether export occurs via direct pumping of the 
metal ion across the plasma membrane or through copper loading of vesicles which are then 
exocytosed is unknown. 
Patients suffering from Menkes disease exhibit copper overload within the intestine due to 
compromised export into the general circulation which in turn produces a severe copper deficiency in 
most peripheral tissues (Danks et al., 1973; Kaler, 2013). This peripheral copper deficiency results in 
loss of copper-dependent enzyme activities and leads to severe neurological defects. Currently there 
is no cure for Menkes disease; however, subcutaneous and intracardiac injections of copper into the 
blood stream can help delay the onset of neurological symptoms in some patient backgrounds (Kaler 
et al., 2008). As the predominant function of ATP7B is to pump excess copper into the bile, hepatic 
copper overload and eventual toxicosis is a primary symptom of Wilson disease patients (Kaler, 2013). 
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Treatment for Wilson disease involves chelation therapy, a strategy in which copper within the blood 
and tissues is bound to promote its subsequent excretion (Bandmann et al., 2015).  
 
1.1.3 Copper trafficking and storage within the cell 
The toxic properties of copper necessitate that the bioavailability of the metal ion be tightly 
controlled and it is estimated that on average there is less than one free copper atom per cell (Rae et 
al., 1999). To regulate the amount of free intracellular copper while allowing for its proper trafficking, 
the metal ion is typically bound to peptides or proteins including glutathione (GSH), metallothioneins 
or other dedicated chaperones (Prohaska and Gybina, 2004). The first of these, the tripeptide GSH, is 
the major determinant of redox balance within the cell, as in its reduced form GSH can act as an 
electron donor to neutralize dangerous oxidative molecules from the cellular environment (Valko et 
al., 2006). GSH also binds to and sequesters copper in vivo to prevent copper toxicity, and its cellular 
concentration actually increases under conditions of copper overload (Freedman et al., 1989). Fitting 
with a role in maintaining cellular copper homeostasis, GSH is required for copper import into the 
cell (Maryon et al., 2013b), and a Drosophila melanogaster model with genetically depleted GSH 
levels in neurons has a lethal phenotype, with flies exhibiting unexpanded wings and decreases in 
axon branching, characteristics reminiscent of a copper deficient phenotype (Mercer et al., 2016). 
Further, the lethal phenotype is partially rescued with copper supplementation and exasperated by the 
knockdown of Ctr1 (Mercer et al., 2016). The second protein involved in the sequestration of cellular 
copper is the low molecular weight protein metallothionein. Mammals express multiple forms of 
metallothionein that vary in size; however, they all contain multiple, cysteine rich motifs which are 
used to bind copper and other heavy metals (Hamer, 1986). Like GSH, metallothionein expression is 
increased under conditions of copper excess (Freedman et al., 1989; Fürst et al., 1988) to buffer against 
copper toxicity, and mice lacking both metallothionein I and II have a much lower LD(50) for copper 
than wild-type littermates indicating an increase in copper sensitivity (Park et al., 2001). 
The last and most important class of copper-binding proteins is comprised of dedicated 
chaperones, which bind copper and deliver it to specific proteins that require the metal ion for their 
function. The yeast protein ATX1 was the first of these proteins to be discovered (Klomp et al., 1997; 
Lin and Culotta, 1995; Lin et al., 1997). Both ATX1 and its human homolog ATOX1 have since been 
shown to play direct and important roles in oxidative defence (Hatori et al., 2012; Lin and Culotta, 
1995). However, their primary function is to deliver copper to the P-type ATPases ATP7A and ATP7B 
for subsequent maturation of secreted cuproenzymes. Consistent with this idea, both atx1Δ yeast and 
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Atox1 knockout mice display significant decreases in the activity of extracellular cuproenzymes 
(Hamza et al., 2001; Lin et al., 1997). Under high copper conditions ATOX1 can also form a dimer 
and re-localize to the nucleus (Itoh et al., 2008), where it binds to ATOX1-specific promoter elements 
and transactivates the expression of genes encoding factors involved in cell proliferation (Cyclin D) 
and the removal of free radicals (Sod3) (Itoh et al., 2008, 2009). Translocation of the ATOX1 dimer 
through the nuclear pore is conceivable given that its mass is 14.8kDa, and the pore can accommodate 
proteins of up to 60 kDa (Wang and Brattain, 2007).  
The copper chaperone for superoxide dismutase (CCS) is another dedicated copper chaperone 
within the cell. CCS has two known functions; to deliver copper within the cytosol to the Cu/Zn form 
of superoxide dismutase, SOD1, and to catalyze the formation of a critical intramolecular disulphide 
bond within SOD1. Both SOD1 metallation and disulphide bond formation are not essential for 
protein stability (Bartnikas and Gitlin, 2003), but are needed for proper protein folding and catalytic 
competence (Culotta et al., 1997; Furukawa et al., 2004). CCS is also localized to the mitochondrial 
intermembrane space (IMS) where it similarly promotes the maturation of a small but physiologically 
significant fraction of SOD1 (Sturtz et al., 2001). Interestingly, the abundance of CCS depends on the 
bioavailability of copper, with CCS protein levels being inversely correlated with dietary copper levels 
(Bertinato et al., 2003; Prohaska et al., 2003). Copper-dependent regulation of CCS abundance is 
maintained in a fibroblast CCS overexpression model with changes in extracellular copper 
concentrations (Caruano-Yzermans et al., 2006), suggesting that the regulation of CCS abundance 
occurs post-translationally. Fitting with this model, treatment of cells with the proteasome inhibitor 
MG132 prevented the degradation of CCS even upon culture in high copper conditions (Caruano-
Yzermans et al., 2006). With the abundance of CCS being so tightly correlated with cellular copper 
status, the protein is thought to be a reliable biomarker of copper availability (West and Prohaska, 
2004), and CCS abundance within erythrocytes can be used as a sensitive measure of copper 
deficiency (Lassi and Prohaska, 2011, 2012).  
The mitochondrial protein COX17 is at the head of a pathway of copper chaperones within the 
organelle that function collectively to deliver and insert copper into cytochrome c oxidase (COX), the 
terminal enzyme of the electron transport chain. How copper chaperones deliver copper to COX and 
how this pathway is tied to the regulation of copper homeostasis will be discussed below.  
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Figure 1.3: Pathways of mammalian mitochondrial copper acquisition and trafficking 
Dietary copper (Cu2+) is reduced extracellularly by a member of the STEAP family of oxidoreductase 
proteins. The high affinity copper transporter CTR1 can then transport the reduced cuprous (Cu+) ion 
across the plasma membrane into the cytosol. Copper is targeted to the mitochondria via an unknown 
mechanism, however, the ion is bound to an unidentified organic ligand (CuL) within the cytosol 
which is thought to facilitate its transport across the inner-mitochondrial membrane into the matrix. 
This mitochondrial copper import is accomplished by SLC25A3, the mammalian homolog of the yeast 
phosphate transporter Pic2. Matrix copper is pumped back into the IMS and is used to metallate the 
cuproenzymes that reside there, COX and SOD1. This metallation occurs through protein specific 
chaperones such as CCS, COX17, SCO1, and COX11. Despite the characterization of these copper 
handling pathways there exist many other mitochondrial proteins known to be involved in COX 
assembly which have unknown functions but may involved in protein metallation, including COX23, 
COA5 and CMC1-3. (Figure from Baker et al., 2017) 
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1.1.4 Copper within the mitochondrion 
In addition to copper trafficking pathways, the cell can store the metal ion in concentrated labile 
pools, one of which is localized to the mitochondrial matrix (Figure 1.3) (Cobine et al., 2004; Leary 
et al., 2009). Fitting with a role in sequestration of copper, the mitochondrial copper pool is dynamic 
in nature and can expand during cellular copper overload, presumably protecting the rest of the cell 
from copper toxicity (Bhattacharjee et al., 2016; Cobine et al., 2004). The storage capacity within the 
organelle is not limitless, however, as patients with Wilson disease who accumulate high amounts of 
hepatic mitochondrial copper exhibit severe perturbations in mitochondrial ultrastructure and function 
(Roberts et al., 2008; Sternlieb, 1968; Zischka and Lichtmannegger, 2014). Symptoms attributable to 
supranormal levels of mitochondrial copper are reversible upon treatment with methanobactin, a 
copper chelator capable of reducing the amount of copper contained within the organelle 
(Lichtmannegger et al., 2016). The mitochondrial matrix copper pool is used to metallate the two 
known cuproenzymes within the IMS, SOD1 and COX, and its targeted depletion greatly reduces the 
activity of both enzymes (Cobine et al., 2006a). These enzymes are critical for proper cellular function 
and, as such, the cell places a premium importance on maintaining adequate levels of mitochondrial 
copper under whole cell copper deficiency (Dodani et al., 2011; Hlynialuk et al., 2015), even at the 
expense of other organelles (Merchant and Bogorad, 1986; Merchant et al., 2006). 
How copper is delivered to the mitochondrion is unknown. The COX assembly factor COX17 
was previously hypothesized to perform this function, as it is known to partition between both the 
cytosol and IMS in yeast and humans (Glerum et al., 1996; Oswald et al., 2009); however, a 
cox17Δyeast strain has normal mitochondrial copper levels and strains expressing a version of 
COX17 tethered to the inner mitochondrial membrane have wild-type levels of COX and IMS-SOD1 
activity (Cobine et al., 2004; Maxfield et al., 2004). Independent of the mechanisms that deliver 
copper to the organelle, its storage within the matrix requires at least one transporter owing to the 
impermeability of the inner mitochondrial membrane. Recently, studies in yeast have implicated the 
mitochondrial carrier family proteins Pic2 and Mrs3 as copper transporters (Vest et al., 2013, 2016). 
Although Pic2 and Mrs3 are known phosphate and iron transporters respectively, each also exhibits 
copper transport activity in vitro (Vest et al., 2016). Furthermore, a double pic2Δmrs3Δyeast strain 
has greatly reduced mitochondrial copper stores and a deficiency in COX and IMS-SOD1 activities 
(Vest et al., 2016). The closest human orthologue to yeast Pic2, SLC25A3, can rescue copper transport 
in pic2Δ yeast strains, suggesting that this mechanism for mitochondrial copper transport is 
evolutionarily conserved (Boulet et al., 2017). Fittingly, SLC25A3 knockdown or deletion in mouse 
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or human fibroblasts results in an isolated COX deficiency, which can be rescued with the addition of 
excess copper to the media (Boulet et al., 2017). Copper within the mitochondrial matrix is bound to 
an as of yet unidentified anionic ligand and it is thought that formation of the copper ligand complex 
promotes its translocation across the inner mitochondrial membrane (Cobine et al., 2004). How copper 
is exported back into the IMS, where it then interacts with specific chaperones required for copper 
delivery to SOD1 and COX is unknown. 
 
1.2 Assembly of the COX CuA site 
1.2.1 COX and the electron transport chain 
The conversion of nutrients to a usable form of energy is essential for all living organisms. 
Ultimately, the primary goal of this conversion process is to generate ATP, the energy currency within 
the cell. Hydrolysis of ATP to ADP releases substantial amounts of free energy that can then be 
coupled to unfavourable endergonic reactions. The bulk of ATP is generated within the mitochondrion 
where reducing equivalents generated through catabolism supply electrons that are subsequently 
transferred through the complexes of the electron transport chain (ETC). These redox reactions are in 
turn coupled to the transport of protons from the mitochondrial matrix to the IMS to generate the 
proton motive force that is ultimately harnessed by ATP synthase (Complex V) to convert ADP into 
ATP. The ETC consists of 4 enzymatic complexes: NADH dehydrogenase (Complex I), Succinate 
Dehydrogenase (Complex II), Ubiquinone:Cytochrome c oxidoreductase (Complex III) and 
Cytochrome c oxidase (COX/Complex IV). 
COX is the final complex of the ETC and catalyzes the transfer of electrons from cytochrome c 
to molecular oxygen to produce water while simultaneously pumping protons across the mitochondrial 
inner membrane. COX is a multimeric protein complex and assembly of the holoenzyme is a 
complicated process. In mammals, COX contains 14 subunits that are encoded by both the 
mitochondrial and nuclear genomes (Table 1.1). Three of its subunits, COX1-3, are conserved from 
α-proteobacteria and are encoded by the mitochondrial genome. These proteins represent the catalytic 
core of the holoenzyme and contain the metal co-factors required for catalytic competence; two heme 
groups (heme a and a3) and two copper sites (CuA and CuB). The binuclear CuA site is located within 
the IMS in a solvent exposed portion of COX2 and it is involved in the first step of catalysis, accepting 
electrons upon the oxidation of cytochrome c (Figure 1.4). Electrons are transferred sequentially to 
the heme a group within the transmembrane domain of the COX1 subunit, then to the binuclear 
CuB:heme a3 centre, and finally to an oxygen molecule on the matrix side of the membrane. The 11 
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nuclear-encoded subunits represent the “structural” subunits of the holoenzyme. These proteins act as 
a protective structural scaffold to stabilize the catalytic core of the enzyme, offer regulatory sites for 
the allosteric modulation of COX activity (Acin-Perez et al., 2011) and provide physical interfaces 
for interactions with other ETC enzymes that allows for the formation of respiratory super-complexes 
(Ikeda et al., 2013). Many of these nuclear-encoded subunits also have tissue-specific isoforms and 
can undergo post-translational modifications which affect COX function and add further regulatory 
complexity to the system (Kadenbach and Hüttemann, 2015).  
With so many variable components from different sources, the assembly of the COX 
holoenzyme is an increasingly complex process that is constantly being updated. Currently, COX 
assembly is believed to occur in a linear and modular hybrid model (Timón-Gómez et al., 2017). The 
catalytic subunits of the holoenzyme (COX1-3) are matured as individual modules, which requires 
their insertion into the membrane, the addition of their metal co-factors and in some cases the 
incorporation of a subset of additional, nuclear-encoded COX subunits. These subassembly modules 
are subsequently integrated into a linear pipeline in which the remaining structural subunits are added 
sequentially to yield the fully functional COX holoenzyme (Figure 1.5). The complex assembly of the 
COX holoenzyme is facilitated by a large number of proteins termed COX assembly factors.  
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Table 1.1: COX structural subunits 
List of all known mammalian COX subunits. COX1-3 make up the catalytic core of the enzyme and 
are encoded within the mitochondrial genome. The other 11 subunits are structural subunits, encoded 
within the nuclear genome and imported into the mitochondria for assembly. 
CORE COX SUBUNITS 
COX1 
COX2 
COX3 
STRUCTURAL SUBUNITS 
COX4 
COX5A 
COX5B 
COX6A 
COX6B 
COX6C 
COX7A 
COX7B 
COX7C 
COX8 
NDUFA4 
 
Figure 1.4: Electron flow through the catalytic core of cytochrome c oxidase 
Cytochrome c oxidase (COX) collects an electron through the oxidation of cytochrome c. This 
electron is first received by the binuclear CuA site in the IMS portion of the COX2 subunit. From here 
the electron is passed to the Heme a group, and then to the binuclear Heme-a3: CuB site both of which 
are located within the COX1 subunit. Finally, the electron is passed to reduce molecular oxygen and 
generate a molecule of water.  
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Figure 1.5: COX assembly pathway 
COX is thought to be assembled in a hybrid between linear and modular models. COX core subunits 
(black) are first assembled into subassembly complexes featuring structural subunits (green), and 
metal cofactors (red). Following insertion into the membrane and addition of CuB, Heme A, and Heme 
A3 groups, COX1 first forms a complex with COX4:COX5A. This complex then comes together with 
the other subassembly complexes containing COX2 and COX3 as well as other structural subunits to 
make the ultimate holoenzyme (COX). Many assembly factors are involved in all processes of this 
assembly. Those involved in the insertion of the metal cofactors are included here (blue). 
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1.2.2 COX assembly factors 
At present there are more than 30 known COX assembly factors in mammals (Table 1.2) 
(reviewed in Timón-Gómez et al., 2017), although this number continues to expand with more 
research (Vidoni et al., 2017). These accessory proteins perform a variety of different functions 
important to RNA stability and translation, protein insertion into and stability within the inner 
mitochondrial membrane, and synthesis, delivery and insertion of the heme and copper co-factors. 
Almost all COX assembly factors were first discovered in Saccharomyces cerevisiae as petite mutants 
with an isolated COX deficiency (McEwen et al., 1986; Tzagoloff and Dieckmann, 1990), and their 
human orthologues identified by mapping disease genes in patients who presented with an isolated 
COX deficiency (Tiranti et al., 1998; Zhu et al., 1998). Other genes involved in COX assembly were 
identified using suppressor screens in yeast and cultured cells to identify genes or proteins which 
reverse the bioenergetic defect (Barros et al., 2004; Glerum et al., 1996). Identified assembly factors 
have allowed for significant advancement in the understanding of holoenzyme assembly through the 
study of stalled COX assembly intermediates that occur in their absence. Now, with the advent of next 
generation and exome sequencing, the rate of discovery of pathogenic mutations in human patients 
with mitochondrial diseases caused by an isolated COX deficiency or other genetic lesions has 
increased significantly, resulting in a significant growth in the characterization of proteins with 
previously unknown functions (Lyons et al., 2016; Wortmann et al., 2015). We will now restrict our 
focus to those proteins with known roles in the assembly of the CuA site of COX. 
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Table 1.2: COX assembly factors 
List contains all known COX assembly factors along with the function for those identified. Assembly 
factors which have been indicated to be involved in the metallation of the enzyme are coloured in blue 
and those with unknown functions are coloured in gold. 
 
COX ASSEMBLY FACTOR FUNCTION 
LRPPRC mitochondrial mRNA stability 
TACO1 COX1 mRNA translational activator 
OXA1L Membrane insertion of COX subunits 
COX20 COX2 chaperone 
COX18 Export of the COX2 C-terminus 
COX17 
Cu chaperone involved in both CuA and CuB 
site formation 
SCO1 Transfer of copper to COX2 
SCO2 Reduction of COX2 CX3C motif 
COA6 Involved in CuA metallation 
COX11 Involved in CuB metallation 
COX19 Involved in CuB site formation 
COX10 Farnesylation of heme B 
COX15 Involved in heme O oxidation 
FDX2 Involved in heme O oxidation 
ADR Involved in heme O oxidation 
SURF1 Involved in heme A delivery 
CMC1 
Stabilizes COX1 with COX14 and COA3 
possibly involved in metallation  
COX14 Required for COX1 stability 
COA3 Required for COX1 stability 
COA1 Required for COX1 stability 
HIGD1A Stabilizes COX4:COX5A complex 
MITRAC7 Stabilizes COX1:COX4:COX5A complex 
MR-S1 
Involved in the formation of late assembly 
intermediates 
PER100 
Involved in the formation of late assembly 
intermediates 
PET117 
Involved in the formation of late assembly 
intermediates 
HIGD2A Supercomplex formation 
PET191 Unknown function 
CMC2 Unknown function 
COX23 Unknown function 
COX16 Unknown function 
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1.2.3 Assembly of the CuA site within COX2 
Copper used for the metallation of the CuA site comes from the labile pool sequestered within 
the mitochondrial matrix. This copper crosses back into the IMS, through an unknown mechanism, 
and is bound by the copper chaperone COX17 (Beers et al., 1997; Glerum et al., 1996). Copper-loaded 
COX17 subsequently delivers the metal ion to at least three other cuproproteins within the IMS; 
COX11, which is involved in the metallation of the CuB site, and SCO1 and SCO2, which are required 
for copper insertion into the CuA site (Horng et al., 2004). SCO1 and SCO2 are paralogs that were 
first identified in a high copy suppressor screen of a Cox17 point mutant (Glerum et al., 1996). Both 
proteins use an evolutionarily conserved CxxxC motif and a distal histidine residue to bind copper, 
which is essential for their function as point mutants within the copper binding site result in a non-
functional COX (Nittis et al., 2001). COX17 donates copper to each SCO protein via transient ligand 
exchange, and in the case of SCO1, this reaction may be coupled with electron transfer to reduce the 
CxxxC motif to prime it for copper-loading (Banci et al., 2008; Horng et al., 2004). 
Once copper bound, SCO1 and SCO2 form a ternary complex with a third protein, COA6, that 
physically associates with the COX2/COX20 complex within the inner membrane (Figure 1.6) 
(Bourens and Barrientos, 2017). The exact function of each protein within the SCO1/SCO2/COA6 
complex is still an active area of research. SCO1 is known to directly bind COX2 using critical amino 
acids within loop 8 (Lode et al., 2000; Rigby et al., 2008), and in vitro experiments demonstrated that 
SCO1 is specifically involved in copper transfer to COX2 (Morgada et al., 2015). These in vitro 
analyses also identified SCO2 as a disulphide reductase that reduces the copper-binding cysteinyl 
sulphurs of COX2 (Morgada et al., 2015). COA6 is a small, soluble protein of unknown function 
which has been shown to be essential for the metallation of the CuA site in both yeast and humans 
(Ghosh et al., 2014). COA6 binds SCO1, SCO2 and COX2 which points to a possible role in 
facilitating the formation or promoting the stabilization of the ternary complex required for CuA site 
maturation (Ghosh et al., 2016; Pacheu-Grau et al., 2015; Stroud et al., 2015); however, COA6 has 
been hypothesized to bind copper and therefore may have a role in removing the Cu2+ from SCO2 
after the protein reduces COX2, thereby priming SCO2 for multiple rounds of copper binding (Ghosh 
et al., 2016). COX2 receives copper from SCO1 and binds the metal ion using two conserved 
cysteines, two histidines, a glutamate and a methionine residue, all of which reside within a 
cuproredoxin fold (Speno et al., 1995). Once the assembly of the CuA site is complete the COX2 
module is incorporated into the maturing holoenzyme. 
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Figure 1.6: Relative roles of SCO1 and SCO2 in the metallation of the CuA site 
(Top) Both SCO1 and SCO2 function as homodimers functioning within a complex that includes the 
soluble IMS protein COA6. SCO1 and SCO2 receive copper from COX17 in the cupric (Cu+) form. 
(Middle) In vitro studies have suggested that SCO2 then functions to reduce the cysteinyl sulphurs of 
COX2, while oxidizing its own copper ions to the cuprous (Cu2+) form. (Bottom) COX2 is now able 
to accept cupric copper donated from SCO1.  
 
  
19 
 
1.2.4 The role of COX assembly factors in maintaining cellular copper homeostasis 
Much of the work done to characterize assembly of the CuA site has come from studying patients 
affected by pathogenic mutations in genes encoding factors crucial to this process. Human patients 
have been described for 3 different proteins involved in generating the CuA site, SCO1 (Leary et al., 
2013a; Stiburek et al., 2009; Valnot et al., 2000), SCO2 (Papadopoulou et al., 1999) and COA6 
(Baertling et al., 2015). These patients all predictably presented with an isolated COX deficiency 
stemming from an inability to properly assemble the holoenzyme. Interestingly, however, affected 
tissues from patients with mutations in SCO1 and SCO2 not only exhibited a profound COX 
deficiency but also a deficiency in total cellular copper suggesting that these proteins may have an 
additional role in maintaining cellular copper homeostasis (Leary et al., 2007). So far more than 50 
SCO2 pedigrees have been discovered (Pronicka et al., 2013), with almost all containing at least one 
E140K allele and presenting with a fatal hypertrophic cardio-encephalopathy (Jaksch et al., 2000; 
Papadopoulou et al., 1999; Vesela et al., 2004). Patients homozygous for the E140K mutation have a 
less severe phenotype than their compound heterozygous counterparts (Jaksch et al., 2001), suggesting 
that the E140K variant is more functional than other pathogenic mutations. Consistent with this idea, 
overexpression of SCO2 E140K can rescue the COX deficiency in SCO2 patient cells (Leary et al., 
2007).  
Contrary to the large number of discovered SCO2 pedigrees, only three SCO1 pedigrees have 
been identified to date and patients from each pedigree present with clinically heterogeneous, fatal 
forms of disease. The first pedigree, harbouring a nonsense mutation on one allele and a proline to 
leucine substitution at position 174 on the other allele, presented neonatally with lethal hepatopathy 
and encephalopathy (Valnot et al., 2000). The second SCO1 pedigree was homozygous for a glycine 
to serine substitution at position 132. The patient died at 6 months of age and presented with 
hypertrophic cardio-encephalopathy as well as a very mild hepatopathy (Stiburek et al., 2009). The 
third, and most recently identified SCO1 pedigree, harboured a nonsense mutation on one allele and 
a methionine to valine substitution on the other allele (Leary et al., 2013a). The patient died at 5 
months of age from a severe encephalopathy and, interestingly, had an unaffected liver and heart 
(Leary et al., 2013a). The cause of the unique tissue-specific phenotypes in each of the SCO1 pedigrees 
is unknown, although it may be that the individual missense mutations differentially impinge upon 
one or both functions of SCO1. 
Since the P174L mutation is adjacent to the CxxxC copper-binding motif (Figure 1.7), it was 
originally hypothesized that the mutation may affect the ability of the protein to bind copper. This 
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hypothesis, however, is likely an oversimplification as even though the mutant protein binds copper 
normally in vitro (Cobine et al., 2006b) and the COX deficiency phenotype can be partially rescued 
in patient fibroblasts by supplementing the culture media with copper salts (Leary et al., 2004), the 
P174L changes the structure of the protein enough that it abolishes its interaction with COX17 and 
prevents ligand exchange reactions between the two proteins in vivo (Banci et al., 2007; Cobine et al., 
2006b). The G132S mutation is near the transmembrane helix, within the portion of SCO1 involved 
in protein dimerization (Stiburek et al., 2009). The mutation disrupts SCO1 dimerization and the 
mutant protein appears to migrate only in its monomeric form under native conditions (Stiburek et al., 
2009). Overexpression of the G132S mutant causes a dominate negative effect on COX activity when 
overexpressed in control or SCO1 patient fibroblasts from other backgrounds, further suggesting that 
the inability of the mutant protein to dimerize disrupts its function (Leary et al., 2013a). While both 
the P174L and G132S substitutions alter specific properties of the protein crucial to its function 
thereby resulting in a severe, combined COX and copper deficiency, the M294V mutation appears to 
predominantly affect protein folding (Leary et al., 2013a). However, patient fibroblasts with this 
mutation have a milder COX deficiency and overexpression of the M294V SCO1 variant fully rescues 
the COX deficiency in two different SCO1 patient backgrounds, arguing that the residual mutant 
protein that is able to properly fold is functional (Leary et al., 2013a). 
 
 
Figure 1.7: Location of critical amino acids within SCO1 
Schematic drawing of the SCO1 protein with critical copper binding residues listed in red and 
identified pathogenic mutations in blue. The first 66 amino acids of SCO1 represent the mitochondrial 
targeting sequence of the protein and are cleaved upon translocation into the mitochondria. The region 
of 118-131 is critical for dimerization of SCO1 molecules, and the G132S mutation immediately 
following this region predictably affects homodimer formation. The CX3C motif at residues 169-173 
is critical for copper binding, however, the P174L mutation immediately following this region does 
not affect copper binding but instead results in an inability for SCO1 to be properly metallated by 
COX17. The third critical residue involved in copper binding is the histidine at position 260, which 
functions as a molecular lid keeping the copper bound. Finally, the last identified pathogenic mutation 
is the M294V mutation that results in an unstable rapidly degraded protein. 
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2. RATIONALE AND OBJECTIVES 
2.1 Rationale and hypothesis 
Despite the importance of dysregulation of copper homeostasis to the etiology of several human 
diseases, little is known about how copper levels are sensed and regulated at the cellular and whole 
organ levels. It is clear, however, that mitochondria have an essential yet poorly understood role in 
this process. Existing literature argues that the mitochondrial inner membrane protein SCO1 is central 
to a copper sensing pathway whose signalling activity is critical to maintaining cellular copper levels. 
We hypothesize that the deletion of Sco1 in mouse tissues will similarly affect copper homeostasis, 
thereby providing a model system that may shed light on the downstream mechanisms relevant to the 
maintenance of cellular copper levels that are specific to individual human tissues. Our focus on the 
liver and heart in these studies reflects the fact these are two of the most severely affected tissues in 
SCO1 patients described to date. 
As perturbations in SCO1 function are known to selectively affect distinct tissues for reasons 
that remain unclear, we require a model system amenable to the biochemical analysis of multiple 
tissues. Using transgenic mice therefore allows us to investigate how SCO1 protein function impinges 
upon copper homeostasis in the tissues in situ and examine whether the associated homeostatic 
mechanisms differ between organs where systemic influences remain intact. Other, simpler model 
organisms or cultured cells are not tractable in this context. 
 
2.2 Specific objectives 
1) To generate tissue-specific Sco1 knockout mouse models in which the gene is specifically 
deleted in the liver or the heart.  
2) To characterize these tissue-specific Sco1 knockout mouse models on a biochemical, 
physiological, molecular, and elemental level.  
3) To investigate the mechanisms by which ablation of Sco1 expression in the liver and heart causes 
a cellular copper deficiency and determine if these mechanisms differ between the two tissues. 
4) To generate and characterize a knock-in mouse model harbouring a Sco1 G115S missense 
mutation which in humans causes cardiac dysfunction and determine the extent to which it 
phenocopies the relevant SCO1 pedigree and the heart-specific Sco1 knockout models. 
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3. MATERIALS AND METHODS 
3.1 Generation of model organisms 
3.1.1 Generation and validation of tissue-specific Sco1 knockout mice 
Embryonic stem (ES) cells containing loxP sites flanking the second exon of Sco1, and frt sites 
flanking a Neomycin cassette with a lacZ gene, were purchased from the Knockout Mouse Project 
Repository (Figure 3.1). Deletion of the second exon in Sco1 generates a premature stop codon 
resulting in the degradation of the Sco1 transcript via that nonsense mediated decay pathway. These 
“floxed-Neo” ES cells were used to generate male chimera transmitter mice, through morula 
aggregation, by the Toronto Centre for Phenogenomics and germline transmission of the modified 
Sco1 allele was verified. Following shipment to the University of Saskatchewan, verified male mice 
containing the “floxed-Neo” Sco1 were crossed to C57BL/6N females, and subsequent progeny were 
intercrossed for multiple generations. Female Sco1flox-Neo/flox-Neo mice were next crossed to male 
C57BL/6N mice expressing the FlpE recombinase (Taconic), collapsing the frt sites to remove the 
Neomycin cassette and lacZ gene. Resultant heterozygous mice were intercrossed to generate 
homozygous mice containing a collapsed frt site and the floxed second exon of Sco1 (herein referred 
to as Sco1flox/flox mice). To generate all tissue-specific knockout mice, female Sco1flox/flox mice were 
first crossed to male C57BL/6N mice expressing Cre recombinase under the expression of either the 
liver-specific albumin promoter (for Sco1liv/liv mice, Jackson Laboratories #003574), the heart-specific 
α-myosin heavy chain promotor (for Sco1hrt/hrt mice, Jackson Laboratories #018972), or the striated 
muscle-specific muscle creatine kinase promotor (for Sco1stm/stm mice, Jackson Laboratories 
#006475). F1 progeny from these crosses (Cre+/-, Sco1flox/wt), were next back-crossed to the Sco1flox/flox 
mice, generating the tissue-specifc Sco1 knockout mice containing the collapsed second exon of Sco1. 
Genotyping of Sco1 alleles and excision of both frt and loxp sites was confirmed using a common 
three primer PCR mix (Figure 3.1, Table 3.1). Existence of Cre recombinase gene was confirmed 
using a common 4 primer mix (Table 3.1). 
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Figure 3.1: Cre-lox deletion scheme for Sco1 
Schematic depicting wild-type Sco1 gene with exons and introns (top). Embryonic stem cells were 
first generated having loxP (triangles) sites flanking the second exon of Sco1 and contained both a 
lacZ gene and a Neomycin resistance cassette flanked by frt (diamonds) sites (Floxed-Neo Sco1). ES 
cells were used to generate founder mice, which were then bred to remove the frt sites leaving the 
loxp sites (Floxed Sco1). Finally, to generate knockouts the Floxed Sco1 mice were bred to mice 
expressing Cre recombinase, excising the region of DNA between the loxp sites (Deleted Sco1). 
Primers listed (P1-3) depict 3 primer PCR used to genotype wild-type, floxed, and deleted alleles. 
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Table 3.1: PCR Primer List 
List contains details for all primers and probes used for PCR, including primer name, 5’-3’ 
sequence, and the function of the reaction they were included in. + indicates a locked amino acid. 
Lower case letters in probes represent differences in sequence designed to recognise knock-in 
mutation in Sco1G115S/G115S. 
 
  
Primer Name Sequence (5'-3') Used in
Sco1-P1 GTCACATCTCAGGAACTTCCTGG Genotyping Sco1 WT/flox
Sco1-P2 CCACAACGGGTTCTTCTGTT Genotyping Sco1 WT/flox
Sco1-P3 ACCTAAAAGTGGGGCTTCCTGAAAACTAA Genotyping Sco1 WT/flox
Cre-P1 ATGACAGACAGATCCCTCCTATCTCC Genotyping Cre animals
Cre-P2 CTCATCACTCGTTGCATCATCGAC Genotyping Cre animals
Cre-P3 CAAATGTTGCTTGTCTGGTG Genotyping Cre animals
Cre-P4 GTCAGTCGAGTGCACAGTTT Genotyping Cre animals
G115S-F TTAGAGCTGGAGAAACAACGG Genotyping G115S mice
G115S-R GGCTCTCCATTGTGAGTTGTA Genotyping G115S mice
G115S-WT-Probe CA+TT+g+G+gAA+GCC Genotyping G115S mice
G115S-KI-Probe CA+TT+a+G+cAA+G+CCT Genotyping G115S mice
Sco1 cDNA-F AAAAAGCAGGCTACCATGGCAGCACTTGTACGCGCCGC Overexpression of Sco1
Sco1 cDNA-R CTTCATGTGTGACCTCACGTGTGCAGCAATTGAG Overexpression of Sco1
Ctr1 cDNA-F AAAAAGCAGGCTACCATGAACCATATGGGGATGAACC Overexpression of Ctr1
Ctr1 cDNA-R AGAAAGCTGGGTTCAATGGCAGTGCTCTGTGATG Overexpression of Ctr1
RT-Ctr1- F GTCTTGTTGGCCCAGTGTTT RT-PCR analysis of Ctr1
RT-Ctr1-R GCACCTTAATGTTGGGCTGT RT-PCR analysis of Ctr1
RT-Slc41a2- F CTGGCATGGTTTTGGACA RT-PCR analysis of Slc41a2
RT-Slc41a2-R CCACTTCTCAATGGGTGAG RT-PCR analysis of Slc41a2
RT-Mt1- F GTCCTCTAAGCGTCACCAC RT-PCR analysis of Mt1
RT-Mt1- R GAGCAGTTGGGGTCCATTC RT-PCR analysis of Mt1
RT-Gapdh - F GCCGTGAGTGGAGTCATACT RT-PCR analysis of Gapdh
RT-Gapdh - R ATGGTGAAGGTCGGTGTGAA RT-PCR analysis of Gapdh
RT-Anp - F GCTTCCAGGCCATATTGGAG RT-PCR analysis of Anp
RT-Anp - R GGGGGCATGACCTCATCTT RT-PCR analysis of Anp
RT-Bnp - F GAGGTCACTCCTATCCTCTGG RT-PCR analysis of Bnp
RT-Bnp - R GCCATTTCCTCCGACTTTTCTC RT-PCR analysis of Bnp
RT-aSA - F CCCAAAGCTAACCGGGAGAAG RT-PCR analysis of a Sa
RT-aSA - R CCAGAATCCAACACGATGCC RT-PCR analysis of a Sa
RT-Serca2a - F TGGAACAACCCGGTAAAGAGT RT-PCR analysis of Serca2a
RT-Serca2a - R CACCAGGGGCATAATGAGCAG RT-PCR analysis of Serca2a
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3.1.2 Generation and validation of Sco1 G115S homozygous knock-in mice 
Sco1G115S/wt mice were generated at the Toronto Centre for Phenogenomics. C57BL/6NCrl 
zygotes were co-injected with the guide RNA 5’-GCATTAGCAAGCCTTTACTA-3’, Cas9 mRNA, 
and a single-stranded oligonucleotide repair template with both the desired substitution to induce the 
G115S mutation and a silent mutation to interrupt the protospacer adjacent sequence. Successful 
mutagenesis was then confirmed via the DNA sequencing of PCR amplicons. Mice were crossed to 
C57BL/6NCrl mice and screened for germline transmission, with the resultant mice further back-
crossed for multiple generations. Heterozygous Sco1G115S/wt were shipped to the University of 
Saskatchewan and inter-crossed to generate homozygous Sco1G115S/G115S mice used for 
experimentation. Genotyping of knock-in animals was completed using real-time PCR. Tail DNA 
from both wild-type and knock-in was extracted using the KAPA Mouse Genotyping Kit (KAPA 
Biosystems). 2µL of a 1:1 dilution of tail DNA was used in a 10µL reaction, containing 500 nM 
primers and 250 nM probes (Integrated DNA, Table 3.1), in the PerfeCTa qPCR ToughMix (VWR) 
on an Applied Biosystems Step One Plus Real-Time Thermocycler.  
 
3.1.3 Animal husbandry and tissue collection 
Animals from all models were housed in a 12h light: 12h dark photoperiod and provided with 
food and water ad libitum. Equal numbers of male and female mice were used for all models and 
experimental analysis. Tissues from mature animals used in enzymology, molecular biology, 
elemental and genetic analysis were collected from mice following cervical dislocation and 
immediately flash frozen. Blood from mice was collected from either the superficial temporal vein or 
heart (Sco1liv/liv and Sco1stm/stm), or the chest cavity (Sco1hrt/hrt). Serum was collected using two 
sequential 5-minute spins at 1,000 x g at 4oC. 
 
3.2 Cell culture 
3.2.1 Generation of Sco1 null mouse embryonic fibroblasts 
MEFs were isolated from pregnant Sco1flox/flox females at embryonic day 13-15 (Anand et al., 
2014), cultured and subsequently immortalized using retroviral transduction with telomerase and the 
E7 gene of human papillomavirus (Lochmuller et al., 1999; Yao and Shoubridge, 1999). To generate 
Sco1 knockouts, recombinant Cre recombinase was first purified from transformed Escherichia coli 
and added to Sco1flox/flox MEFs. Sco1 knockout and wild-type cells were passaged to clonal density 
then expanded to ensure a homogeneous population. All cultured cells were maintained in high 
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glucose DMEM with 1.2 M pyruvate, 205 µM uridine and 10% fetal bovine serum at 37oC and 5% 
CO2. 
 
3.2.2 Transfection and retroviral transduction for protein overexpression 
For overexpression of Sco1 and Ctr1 in wild-type and Sco1 knockout MEFs, cDNAs were first 
amplified from Sco1flox/flox isolated mRNA using sequence specific primers (Table 3.1). cDNAs were 
cloned into Gateway-modified retroviral expression vectors (Antonicka et al., 2003), and sequenced 
using Sanger sequencing. Retroviral particles were generated through transfection of retroviral 
expression particles, containing relevant cDNAs, into Phoenix Amphotrophic packaging cell line 
(Leary et al., 2013b) using the JetPrime transfection reagent. MEFs were subsequently stably 
transduced with retroviral particles and successful integration was selected for in fibroblasts using 
media containing 2µg/mL puromycin. 
 
3.3 Immunoblot analysis 
3.3.1 Blue Native Polyacrylamide Gel Electrophoresis 
Blue native polyacrylamide gel electrophoresis (BN-PAGE) was performed as previously 
described elsewhere (McKenzie et al., 2007). Briefly, tissues were isolated from cervically dislocated 
mice and flash frozen on dry ice. Tissues were then resuspended and homogenized in extraction buffer 
(Table 3.3). Sample volume was adjusted to a protein concentration of 2 mg/ml, incubated on ice for 
30 min, and finally centrifuged at 18,000 x g for 5 minutes at 4oC. Equal protein loads (20 µg/lane) 
were resolved within a 6-16% acrylamide gradient gel and transferred to a nitrocellulose membrane 
using a semi-dry transfer system.  
 
3.3.2 Denaturing Polyacrylamide Gel Electrophoresis  
Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) was performed as 
previously described. Tissues were isolated as above, resuspended in RIPA extraction buffer (Table 
3.2) and homogenized using a glass dounce homogenizer on ice. Sample volume was adjusted to a 
protein concentration of 5 mg/ml, incubated on ice for 30 minutes, and finally centrifuged at 12,000 
x g for 10 minutes at 4oC. Equal protein loads were resolved on a precast 4-20% SDS-PAGE gradient 
gel (BioRad) and transferred to a nitrocellulose membrane using a semi-dry transfer system. 
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Table 3.3: Common buffer solutions 
List contains all common buffer solutions used in Methods 
Buffer Solution Contents 
1X PBS 
2.7 mM KCl, 134 mM NaCl, 1.5 mM KH2PO4, 8 mM 
K2HPO4 
TBST 
25 mM Tris (pH 7.4), 137 mM NaCl, 2.5mM KCl 
and 0.05% Tween 20 
PCR reaction buffer 
1X NEB Phusion HF Buffer (50 mM KCl, 1.5 mM 
MgCl2) 200 µM dNTPs, 0.5 µM primers, 1U DNA 
polymerase  
RIPA Extraction Buffer 
50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-
100, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM 
EDTA and 1x Complete protease inhibitor cocktail 
Blue Native 
Homogenization buffer 
20 mM bis-Tris (pH 7.4), 50 mM NaCl, 10% (v/v) 
glycerol and 0.2% (w/v) n-dodecyl -D-maltoside 
ECL solution 
100 mM Tris-HCl (pH 8.5), 225 µM p-coumaric 
acid, 1.25 mM luminol, 2.94 mM H2O2 
Enzymology 
homogenization buffer 
25 mM K2HPO4 (pH 7.4), 5 mM MgCl2, 0.6 mM 
DDM 
COX assay buffer 
25 mM K2HPO4 (pH 7.4), 5 mM MgCl2, 0.6 mM 
DDM, 2.5 mg/ml BSA, 50 µM Reduced cytochrome 
c 
SOD1 assay buffer 
50 mM K2HPO4 (pH 7.8), 100 mM EDTA, 50 mM 
xanthine, 500 µM cytochrome c, 6 nM xanthine 
oxidase 
CS assay buffer 
25 mM K2HPO4 (pH 7.4), 5 mM MgCl2, 1.2 mM 
DDM, 10 mM DTNB, 10 mM Acetyl CoA 
Tyrode's solution 
25 mM HEPES (pH 7.4), 119 mM NaCl, 5 mM KCl, 
2 mM CaCl2, 2 mM MgCl2 and 33 mM glucose 
Liver IF blocking 
solution 
1% BSA, 0.2% fat free milk, 5% v/v goat serum, and 
0.2% Triton X-100 
Heart IF antibody buffer 
0.15 mM NaCl, 15 mM Na3C6H5O7*2H2O, 2% goat 
serum, 1% BSA, 0.05% Triton X-100, 0.02% NaN3 
Heart IF blocking buffer 
 2.7 mM KCl, 134 mM NaCl, 1.5 mM KH2PO4, 
8 mM K2HPO4, 10% goat serum, and 6% bovine 
serum albumin 
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3.3.3 Immunodetection of proteins 
Membranes from Blue native and SDS-PAGE were first blocked for 2 hours in a Tris buffered 
saline solution with 5% milk and Tween 20 (Table 3.2) and incubated over night at 4oC in primary 
antibody (list of primary antibodies is shown in Table 3.3). Membranes were next washed six times 
for 5 minutes in TBST (Table 3.2) and incubated for 60 minutes at room temperature in TBST with 
5% Milk and the appropriate secondary antibody conjugated to horseradish peroxidase (1:2500, 
BioRad). Membranes were developed by incubation for 1 minute in a homemade enhanced 
chemiluminescence solution (ECL, Table 3.2) and visualized with X-ray film or a BioRad 
ChemiDocTM MP Imaging System. 
 
3.4 Enzymatic Assays 
Assays to determine enzymatic activities for cytochrome c oxidase (COX) and citrate synthase 
(CS) were performed as described elsewhere (Leary et al., 2004). For determining total superoxide 
dismutase activity, a modified xanthine oxidase assay was used (McCord and Fridovich, 1969). 
Briefly, small 3 mm3 sections of frozen tissues were resuspended in 100 µL of homogenization buffer 
(Table 3.2) and homogenized using a plastic pestle. Following the determination of protein 
concentration, sample volume was adjusted to 2.5 mg/mL. Volumes of sample in linear increments 
(1, 2, and 4 µL) were incubated in 250 µL of the appropriate reaction mixture (Table 3.2), mixed using 
a pipette, and the change of absorbance was measured at either 550 nm (COX and SOD) and 412 (CS) 
for 3 minutes using a SPECTRA max 340PC 96 well plate reader (Molecular Devices). Changes in 
absorbance were used to calculate specific activities. 
 
3.5 Elemental Analysis 
Samples were isolated, and placed in metal-free, acid washed tubes. Samples were then 
incubated in 40% nitric acid for 1 hour at boiling temperature for digestion, diluted in ultra pure, 
metal-free water and analyzed by ICP-OES (Agilent, 7500ce). Concentrations were determined by the 
comparison to both a standard curve generated using two separate mixed metal standards (Optima) 
and nitric acid “blank” samples. All metal concentrations were normalized to the concentration of 
sulphur to allow for varying protein concentrations. For Sco1hrt/hrt mice, samples were normalized to 
the concentration of zinc to allow for the comparison of samples across different time points.  
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Table 3.3: Primary antibodies used 
List contains all primary antibodies used for immunological techniques. 
Protein Name Source Type 
WGA Molecular Probes 
594-conjugated 
Mouse IgG 
Porin Calbiochem Mouse IgG 
Tubulin Sigma Mouse IgG 
GAPDH Invitrogen Rabbit IgG 
Com-1 39 kD subunit Invitrogen Mouse IgG 
Com-2 70 kD subunit Invitrogen Mouse IgG 
Com-3 Core 1 subunit Invitrogen Mouse IgG 
COX1 Invitrogen Mouse IgG 
COXIV Invitrogen Mouse IgG 
ATPase α-subunit Invitrogen Mouse IgG 
SOD1 Enzo Rabbit IgG 
CTR1 Gift from Dr. Jack Kaplan Rabbit IgG 
CCS Gift from Dr. Joe Prohaska Rabbit IgG 
ATP7A Gift from Dr. Micheal Petris Rabbit IgG 
ATP7B Gift from Dr. Micheal Petris Rabbit IgG 
SCO1 Made in House Rabbit IgG 
Na/K ATPase Millipore Mouse IgG 
Rab5 Abcam Mouse IgG 
EEA1 BD Biosciences Rabbit IgG 
LAMP1 Santa Cruz Rat IgG 
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3.6 Lipid Analysis 
Livers were isolated from Sco1liv/liv mice as described above. Lipids were then extracted and 
resolved using thin-layer chromatography on Silica Gel G-60 TLC plates as described elsewhere 
(Stone et al., 2004). Lipids were visualized by dipping the plate into a solution of 10% cupric sulfate 
and 8% phosphoric acid and heating to 180°C. Triacylglycerol and cholesterol esters were quantified 
by scanning densitometry. 
 
3.7 Immunohistochemical, Immunofluorescent, and TEM imaging 
3.7.1 Tissue perfusion, fixation, and preparation 
To isolate livers from wild-type and liver-specific Sco1 knockout mice, mice were anaesthetized 
with 3% isofluorane and oxygen and perfused with 10-15 mL of PBS at 5 mL/minute kept on ice. For 
TEM analysis, mice were subsequently perfused with 10-15 mL of ice-cold PBS with 2.5% 
glutaraldehyde and 2% freshly made paraformaldehyde (PFA). Livers were removed and minced into 
1 mm3 pieces and stored in the PFA solution at 4oC. Further processing and analysis for TEM was 
performed as described elsewhere (Neuspiel et al., 2005). For immunohistochemistry, mice were 
subsequently perfused with 10-15 mL of ice-cold PBS with 4% PFA and stored in PFA solution 
overnight at 4oC. Fixed livers were then dehydrated and embedded in paraffin blocks. For 
immunofluorescence analysis, livers were fixed in a similar manner as for IHC and placed in a 
protective sucrose solution at 15%, then 20% (w/v) until samples sunk to bottom of the container. 
Samples were then frozen in optical cutting temperature compound within cryomolds, using 
isopentane chilled to -80oC with dry ice. 
To isolate hearts from wild-type and Sco1hrt/hrt mice, mice were first euthanized and chest 
cavities were dissected out. Chest cavities were incubated in 10% formalin for 48 hours to allow for 
fixation. Hearts were dissected out of chest cavities, dehydrated, and embedded in paraffin. To isolate 
hearts from wild-type, Sco1stm/stm, and Sco1G115S/G115 mice, mice were first anaesthetized with 3% 
isofluorane and oxygen, and hearts were dissected out of chest cavity. Hearts were cannulated through 
the aorta and perfused with HEPES buffered Tyrode’s solution (Table 3.2) using a modified 
Langendorff setup. For IHC analysis, hearts were incubated in 10% formalin for 48 hours, dehydrated, 
and embedded in paraffin. For IF analysis hearts were rapidly frozen in optical cutting temperature 
compound using isobutane chilled to -80oC using dry ice.  
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3.7.2 Immunohistochemistry staining and imaging procedure 
For IHC analysis, after preparation, hearts and livers from all mouse models were cut to either 
10- (liver) or 6- (heart) micron sections and these sections were mounted on a Superfrost Plus coated 
slides (Fisher Scientific). Slides were next deparaffinized using xylene, dehydrated with varying 
concentrations of alcohol and then rehydrated. For H&E staining, slides were placed in Mayer’s 
hematoxylin for 10 minutes, differentiated in 70% alcohol and stained with 0.01% Eosin Y for 1 
minute. Slides were then rinsed, dehydrated in alcohol, incubated in xylene for 15 minutes, and finally 
cover slipped. For Perls staining, slides were first incubated in Perls Prussian blue until sufficiently 
stained and then counterstained with Nuclear Fast Red. For Masson’s trichrome staining, slides were 
stained first in hematoxylin for 10 minutes, washed, stained in Scarlet-acid Fuchsin for 10 minutes, 
washed again, stained in Aniline Blue for 5 minutes, and finally differentiated in 1% acetic acid. Slides 
were then washed with alcohol, cleared using xylene and cover slips were placed on. All IHC slides 
were visualized using a light microscope and digital pictures were taken using Virtual Microscopy. 
 
3.7.3 Immunofluorescent protocol and imaging procedure 
Optical cutting temperature frozen tissues from all models were cut to 6-micron sections and 
mounted on Superfrost Plus coated slides (Fisher Scientific) for staining. For liver sections, slides 
were first blocked with Tris buffered saline solution containing BSA, milk, goat serum, and Triton X-
100 (Table 3.2) for 1 hour, washed with PBS, and incubated overnight at 4oC in blocking buffer with 
primary antibodies (Table 3.3). Following primary incubation, slides were washed in PBS and 
incubated in blocking buffer with the appropriate fluorescently conjugated secondary antibody. 
Finally, slides were washed in PBS and mounted with Prolong Gold Antifade Mountant containing 
DAPI (Life Technologies). 
For heart samples, slides were fixed post-sectioning in acetone at -20oC for 10 minutes, washed 
twice in PBS for 5 minutes, and washed once in 25 mM glycine for 10 minutes. For CTR1 and Rab5 
antibody analysis, an additional permeabilization step containing 0.1% Triton X-100 in PBS was 
added. Slides were next blocked in heart-specific blocking buffer containing goat serum and BSA 
(Table 3.2) for 1 hour at room temperature and then incubated overnight in heart-specific antibody 
dilution buffer (Table 3.2) containing primary antibody (Table 3.3) in a humidified chamber kept at 
4oC. Following incubation with the primary antibody, slides were washed twice in PBS for 5 minutes 
and incubated for 1 hour in a humidified chamber at room temperature containing in antibody dilution 
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buffer and appropriate secondary antibodies (Table 3.3). Slides were washed twice in PBS for 5 
minutes before imaging. 
Imaging of stained slides was performed using a ZEISS LSM-700 laser-scanning confocal 
microscope. Fluorescent imaged were obtained concurrently with all image acquisition and 
calculation of correlation coefficient of co-staining (OCC) performed using ZEISS Zen Black imaging 
software. 
 
3.8 Echocardiography 
Echocardiography on Sco1stm/stm mice was performed as described elsewhere (56). Briefly, wild-
type and Sco1stm/stm mice (n=4) at P60 and P90 were anaesthetized with 3% isoflurane for 1–2 minutes, 
and then maintained at 1.5–2% isoflurane after losing the righting reflex. Cardiac function was 
measured with mice laid supine on a heated platform using a high resolution Vevo 2100 ultrasound 
system (VisualSonics, Toronto, ON, Canada) equipped with an MS550 transducer. Left ventricle 
internal diameter end systole (LVIDs) and diastole (LVIDd), fractional shortening and ejection 
fraction were determined from the LV short-axis M-mode view. The heart rate, electrocardiogram 
(ECG), respiratory rate and body temperature of the mouse were monitored throughout the 
experiment. 
 
3.9 Microarray and RT-PCR analysis 
Tissues used for RNA extraction were isolated as described above. Total RNA was extracted 
and purified using RNeasy Mini Kit (Qiagen), with DNase digestion step. Following RNA 
quantification using NanoDrop Spectrophotometer ND-1000 (NanoDrop Technologies, Inc.), cDNA 
was synthesized from 250 ng of total RNA using either the Ambion WT Expression Kit (Microarray 
analysis, Life Technologies) or ProtoScript First Strand cDNA Synthesis Kit (RT-PCR, New England 
Biolabs). For microarray analysis, cDNA was fragmented, labeled with Affymetrix GeneChip® WT 
Terminal Labeling Kit (Affymetrix), and hybridized on Mouse Gene 2.0 ST (Affymetrix) in the 
Genechip® Hybridization oven 640 (Affymetrix) for 17 hours at 45oC and 60 rpm. Genechips were 
washed with Affymetrix Hybridization Wash and Stain kit in a GeneChip® Fluidics Station 450 
(Affymetrix). Genechips were scanned on a GeneChip® scanner 3000 (Affymetrix), and raw 
intensities were read, background corrected, normalized, log2 transformed and summarized at the 
transcript cluster level. Cut-off p-values for dysregulated genes were set at ≤0.05 and successful 
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results were subjected to Ingenuity® Pathway Analysis (Qiagen), with Z-scores being used to rank 
predictions.  
For RT-PCR, equal amounts of reverse-transcribed cDNA were used as the template in PCR 
amplification of transcripts of interest. PCR cycle number and conditions were optimized to ensure 
that amplification was optimal and in the log phase. Primers used for PCR reaction are included in 
Table 3.1. 
 
3.10 Statistical Analysis 
 All error bars represent standard error of the mean. For those values depicted as ratios, the 
standard error of the mean was calculated using a previously validated set of statistical equations 
(Homes and Buhr, 2007). Where indicated, significant differences between experimental groups were 
detected using a two-sample Student’s t-test assuming unequal variance. * - P<0.05, ** - P<0.01, *** 
- P<0.001, and NS - not significant.   
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4. Results 
4.1 The role of SCO1 in maintaining cellular copper homeostasis in the murine liver  
4.1.1 Physiological characterization of liver-specific Sco1 (Sco1liv/liv) knockout mice 
4.1.1.1 Validation of liver-specific Sco1 deletion 
As the first human SCO1 patient to be identified presented with an acute, fatal hepatopathy, we 
decided to use the Cre-lox system to generate a liver-specific Sco1 knockout mouse and examine the 
role of SCO1 in this tissue. Briefly, C57BL6/N mice expressing Cre recombinase under the control 
of the liver-specific albumin promoter (Cre+/+, Sco1wt/wt) were crossed to Sco1 transgenic mice in 
which the second exon was flanked by loxP sites (Cre-/-, Sco1flox/flox). The resultant animals (Cre+/-, 
Sco1liv/wt) were then backcrossed to the homozygous Sco1 floxed model to generate liver-specific Sco1 
knockout mice, herein referred to as Sco1liv/liv mice (for full details on breeding see Materials and 
Methods). Animals of all possible genotypes were born at the expected Mendelian frequencies and 
specific deletion of the Sco1 exon in the liver was confirmed using a three primer PCR strategy (Figure 
4.1A). SCO1 protein was not immunologically detectable in Sco1 knockout livers (Figure 4.1B), while 
its abundance was unaltered in all other somatic tissues analyzed (Figure 4.1C). 
 
4.1.1.2 Liver-specific deletion of Sco1 is lethal with mice having a pronounced growth deficiency 
While Sco1liv/liv mice gained weight normally up to approximately postnatal day 28 (P28), they 
exhibited a severe growth deficiency thereafter and by P57 were runted compared to their wild-type 
littermates (Figure 4.1D,E). The growth deficiency preceded lethality, which was observed as early 
as P45, and Sco1liv/liv mice had a median lifespan of 70 days (Figure 4.1F). Lethality was likely caused 
by liver failure as the Sco1liv/liv mice exhibited hepatomegaly compared to their wild-type littermates 
(Figure 4.1G) and had increased alanine aminotransferase activity in their serum, a biomarker of 
severe hepatopathy (Figure 4.1H). 
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Figure 4.1: Deletion of Sco1 in the liver is lethal and presents with a severe growth deficiency 
(A) PCR analysis of the Sco1 gene determining presence of a floxed (top) or deleted (bottom) second 
exon in various tissues (L= Liver, K= Kidney, H= Heart, Br= Brain, Sp= Spleen) in both wild-type 
(Sco1flox/flox) and liver-specific knockout mice (Sco1liv/liv) at P47. (B) Western blot analysis of SCO1, 
COX IV, and CCS abundance in the livers of both wild-type (Sco1flox/flox) and liver-specific Sco1 
knockout mice (Sco1liv/liv) at P47. Tubulin was used as a loading control. (C) Western blot analysis of 
SCO1, COX IV, and CCS abundance in various tissues in P47 wild-type (flox) and liver-specific Sco1 
knockout mice (liv). Tubulin was used as a loading control. Multiple images for SCO1 represent a 
long and short exposure times (D) Body weight (g) over time for both wild-type (Controls, n=184) 
and liver-specific Sco1 knockout mice (liv, n=38). (E) Wild-type (bottom, Sco1flox/flox) and liver-
specific Sco1 knockout mice (top, Sco1liv/liv) at P57 with ruler for reference. (F) Kaplan-Meier survival 
curve of wildtype (blue, Controls, n=96) and liver-specific Sco1 knockout mice (red, liv, n=17). (G) 
Total body weight (right y-axis, g) and tissue weight (left y-axis, g) in both wild-type (Controls, n=5) 
and liver-specific Sco1 knockout mice (liv, n=5), (BW= Body Weight, H= Heart, Li=Liver, Sp= 
Spleen, K= Kidney, Br= Brain). (H) Total Alanine Transaminase (ALT) activity (μU/mg) in the serum 
of both wild-type (Controls) and liver-specific Sco1 knockout mice (liv) at P57. 
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4.1.1.3 Livers from Sco1liv/liv mice exhibit marked steatosis 
Livers from Sco1liv/liv mice exhibited significant discolouration compared to wild-type livers, a 
phenotype that was manifest upon the onset of the growth deficiency (Figure 4.2A). Using 
transmission electron microscopy (TEM) we determined that this discolouration was caused at least 
in part by an increased number of lipid droplets (Figure 4.2B). This conclusion was confirmed by thin-
layer chromatography, which showed an increase in hepatic cholesterol esters and triglycerides 
(Figure 4.2C,D). Finally, the analysis of microarray data obtained from the livers of both Sco1liv/liv and 
wild-type mice identified remodelling of the hepatic transcriptome and the upregulation of genes in 
pathways crucial to the induction of hepatic steatosis (Figure 4.2E). 
 
4.1.2 Molecular characterization of Sco1liv/liv mice 
4.1.2.1 Sco1 knockout livers exhibit a severe isolated COX deficiency and increased 
mitochondrial content 
To determine the cause of the hepatopathy in Sco1liv/liv mice, we began to characterize their livers 
on a biochemical, molecular and ultrastructural level. Livers from Sco1liv/liv mice had a severe, isolated 
COX deficiency both with respect to enzymatic activity (Figure 4.3A) and holoenzyme abundance 
(Figure 4.3B). The COX deficiency was already severe by P18 and progressively worsened over time. 
Mirroring the decrease in COX activity was a corresponding increase in the activity of citrate synthase 
(CS) (Figure 4.3A), as well as an increase in the abundance of multiple other mitochondrial markers 
such as TOM40, ATPase α, and SOD2 (Figure 4.3B).  Consistent with a compensatory increase in the 
mitochondrial content of Sco1 knockout livers, TEM images also showed that the number of 
mitochondria was higher in livers lacking Sco1 expression (Figure 4.2B). 
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Figure 4.2: Liver-specific knockout of Sco1 results in severe steatosis 
(A) Livers from both wild-type (left, flox) and liver-specific Sco1 knockout mice (liv) at P57. (B) TEM image 
at 3,330X magnification of P57 livers from both wild-type (flox) and liver-specific Sco1 knockout 
mice (liv). Scale bar represents 2 μm. Arrows represent mitochondria. Asterisks represent lipid 
droplets (C) Thin-layer chromotographic analysis of lipid content (CE= cholesterol ester, Tg= 
Triglyceride, FA= Fatty acid, Ch = Cholesterol) in livers from both wild-type (flox) and liver-specific 
Sco1 knockout mice (liv) at P27, P37, and P47. (D) Quantification of triglycerides (TG) and 
cholesterol esters (CE) at P27, P37, and P47 in livers of liver-specific Sco1 knockout mice. (n=6 for 
each at all time points). (E) Ingenuity pathway analysis of microarray data showing both upregulated 
genes (red), and down regulated genes (green) involved in hepatic steatosis in the livers of liver-
specific Sco1 knockout mice. Orange lines represent the activation of specific pathways. Yellow lines 
represent gene expression profiles inconsistent with global pathway prediction. 
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Figure 4.3: Deletion of Sco1 in the liver causes an isolated COX deficiency 
(A) Specific actives of citrate synthase (CS), cytochrome c oxidase (COX), and total super oxide 
dismutase (SOD) in the livers from P18 (black), P27 (white), and P57 (grey) liver-specific Sco1 
knockout mice (n= 4-5) expressed as a percentage of wild-type controls (n=5-7). (Inset) Percentage 
of total SOD activity from Cu,Zn-SOD1 (left), and Mn-SOD2 (right) in wild-type (black, Controls, 
n=5) and liver-specific Sco1 knockout mice (white, liv, n= 4) at P57. (B) Blue Native PAGE (top) 
analysis of the electron transport chain complexes I, II, III, and IV and SDS-PAGE (bottom) 
analysis of the mitochondrial markers SOD2, ATPase α, and TOM40 in wild-type (flox) and liver-
specific Sco1 knockout mice (liv) at P18 and P57 
 
4.1.2.2 Sco1liv/liv mice have a severe hepatic copper deficiency that is accompanied by an 
increase in the levels of iron stored in Kupffer cells 
One of the hallmarks of patients with pathogenic mutations in SCO1 is that affected tissues 
exhibit a combined isolated COX and whole cell copper deficiency. Given that Sco1 knockout livers 
phenocopied affected patient tissues with respect to the COX deficiency, we next looked at their 
cellular copper levels. Livers from P47 Sco1liv/liv mice had significantly lower levels of copper than 
their wild-type littermates, without an appreciable copper deficiency in any of the other peripheral 
tissues that were examined (Figure 4.4A). A similar decrease was observed in the activity of the 
cuproenzyme SOD1 (Figure 4.3A), a common observation under copper-deficient conditions. This 
copper deficiency was observed at P18 and, like the COX deficiency, progressively worsened over 
time (Figure 4.4B). Metal concentrations in other tissues examined remained unchanged at all time 
points (Figure 4.4C). Despite the decrease in cellular copper levels within the Sco1 null livers, the 
total amount of mitochondrial copper was preserved in these cells (Figure 4.4D). Interestingly, we 
also observed a sharp increase in the concentration of iron and a concomitant decrease in the 
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concentration of zinc (Figure 4.4A); however, these changes only occurred in the livers of end stage 
mice, long after the onset of the copper deficiency (Figure 4.4B). Furthermore, upon histological 
analysis we determined that this increase in iron levels was isolated to the Kupffer macrophages 
resident to the liver and not manifest in the Sco1 null hepatocytes themselves (Figure 4.4E). 
 
 
Figure 4.4: Deletion of Sco1 in the liver causes a hepatic copper deficiency 
(A) Total levels of copper (black), iron (white) and zinc (grey) in various tissues (Li= Liver, K= 
Kidney, Sp= Spleen, H= Heart, Br= Brain) from P47 liver-specific Sco1 knockout mice (n=5 for all 
tissues and metals) expressed as a percentage of wild-type controls (n=8 for all tissues and metals). 
(B) Total levels of copper (black), iron (white) and zinc (grey) in livers of liver-specific Sco1 knockout 
mice at P18, P27, P37, and P57 (n=4-5 for all metals at all time points) expressed as a percentage of 
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wild-type controls (n= 4-11 for all metals at all time points). (C) Total levels of copper (Cu, top), iron 
(Fe, middle), and zinc (Zn, bottom) in various tissues (K= Kidney, Sp= Spleen, H= Heart, Br= Brain) 
in P18 (black), P27 (grey), and P37 (white) liver-specific Sco1 knockout mice (n= 4-5) expressed as 
a percentage of age matched wild-type controls (n= 4-11). (D) Total levels of mitochondrial copper 
(black), iron (white), and zinc (grey) in livers of liver-specific Sco1 knockout mice at P18, P27, and 
P57 expressed as a percentage of wild-type controls. Data from panel C was multiplied by citrate 
synthase activity to account for increase in mitochondrial content within hepatocytes. (E) 20X 
magnification of Hematoxylin and Eosin (top) and Perls (bottom) stained sections of livers from both 
wild-type (left, flox) and liver-specific Sco1 knockout (right, liv) mice at P57. Scale bar represents 50 
μm. 
 
4.1.2.3 The copper deficiency in Sco1 knockout livers is driven by a progressive decrease in the 
abundance of the high affinity copper transporter CTR1 
The severe copper deficiency observed in Sco1 knockout livers may be caused by either a defect 
in high affinity copper import or an increase in copper export. To distinguish between these two 
possibilities, we examined the abundance of known copper transporters. The abundance of ATP7B 
was unchanged upon hepatic deletion of Sco1 (Figure 4.5A). In contrast, the levels of ATP7A, another 
protein involved in copper export, were increased in the livers of end stage Sco1liv/liv mice (Figure 
4.5B). Although this may indicate an increase in copper export, the increase in ATP7A abundance 
occurs long after the establishment of the copper deficiency (Figure 4.4A), suggesting that elevated 
export is not driving the initial copper deficiency within the Sco1 knockout liver. We therefore turned 
our attention to the high affinity copper importer, CTR1. The abundance of CTR1 was significantly 
decreased in the livers of Sco1liv/liv mice compared to their wild-type littermates at P27 (Figure 
4.5A,B). CTR1 levels further decreased with little to no immunologically detectable protein being 
observed by P57 (Figure 4.5A). Importantly, although the abundance of CTR1 was unchanged in the 
copper-deficient P18 Sco1liv/liv mice, a high percentage of the protein was mislocalized from the 
plasma membrane at P22, demonstrated by reduced co-localization with the plasma membrane marker 
Na+/K+ ATPase (Figure 4.5C,D). These data collectively point to a significant perturbation in copper 
import within the Sco1 knockout liver. 
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Figure 4.5: Deletion of Sco1 in the liver causes a change of localization and a decrease in the 
abundance of CTR1 
(A) Western blot analysis of ATP7A, ATP7B, CTR1, SCO1, and CCS abundance from the livers of 
wild-type (flox) and liver-specific Sco1 knockout (liv) mice at P18, P27, P37, and P57. Tubulin was 
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used as a loading control. For SCO1, upper band represents true SCO1, lower band represents 
unknown, non-specific, immunoreactive band. (B) Western blot analysis of ATP7A, CTR1, SCO1, 
and CCS abundance from the livers of wild-type (flox) and liver-specific Sco1 knockout (liv) mice at 
P22, P27, P37, and P47. (For A and B) Arrow represents the mature glycosylated form of CTR1, while 
the asterisk represents the truncated form of the protein. Tubulin was used as a loading control. 
Multiple images for SCO1 represent a long and short exposure times. For SCO1, upper band 
represents true SCO1, lower band represents unknown, non-specific, immunoreactive band. (C) 
Immunofluorescence analysis of CTR1 (green) localization in livers of wild-type (Control, top) and 
liver-specific Sco1 knockout (Sco1liv/liv, bottom) mice from panel B. Na+/K+ ATPase (red) was used 
as a marker for plasma membrane. Images were taken at 40X and scale bar represents 10 μm. Co-
stained signal in overlay is shown in yellow. (D) Total copper content (Cu, black) and quantification 
of immunofluorescence correlation coefficient of co-staining between CTR1 and Na+/K+ ATPase 
(OCC, white, n= 7 for all time points) in livers of liver-specific Sco1 knockout mice at P22, P27, P37, 
and P47 expressed as a percentage of wild-type littermates. 
 
4.1.3 Investigating the mechanism of mitochondrial copper signalling 
4.1.3.1 Decreased CTR1 abundance is mirrored in Cox10 but not Lrpprc knockout livers  
The decrease in CTR1 abundance in the livers of Sco1liv/liv mice may be attributable to the lack 
of SCO1 or the isolated COX deficiency. To address this issue, we examined liver-specific knockout 
mice with deletions in two other genes known to be involved in COX assembly, Cox10 and Lrpprc. 
Livers from both knockout mouse models were less affected than their Sco1liv/liv counterparts and had 
an increase in the abundance of SCO1 (Figure 4.6A,B). Although both Cox10 and Lrpprc knockout 
livers exhibited comparable decreases in COX activity and copper levels (Figure 4.6A), only the 
Cox10 knockout livers displayed a decrease in CTR1 abundance (Figure 4.6B). CTR1 levels were 
comparable in Lrpprc knockout and wild-type livers, although loss of LRPPRC function resulted in a 
significant increase in the abundance of ATP7A (Figure 4.6A). To further confirm that the abundance 
of CTR1 was not correlated with COX activity, we looked at its steady-state levels in rho0 cells, which 
lack mitochondrial DNA. Rho0 cells had only a modest reduction in CTR1 abundance (Figure 4.6C), 
further suggesting that the signalling mechanism that leads to a reduction in CTR1 levels is not the 
direct result of lower residual COX activity.  
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Figure 4.6: Changes in CTR1 abundance are not correlated with a general energy deficiency 
(A) Levels of total copper (Cu), cytochrome c oxidase activity (COX), and total superoxide 
dismutase activity (SOD) in livers of liver-specific knockouts of Sco1 (black), Cox10 (white, n= 8 
for each measurement), and Lrpprc (grey, n= 3 for each measurement) at P57 expressed as a 
percentage of wild-type controls (n= 6 for Cox10, n= 3 for Lrpprc). Sco1 data is included from 
Figure 3A and 4C for reference. (B) Western blot analysis of ATP7A, CTR1, SCO1 and SCO2 
abundance from livers of wild-type (flox) and liver-specific Lrpprc (left), Sco1 (middle), and Cox10 
(right) knockout (liv) mice at P70 (Lrpprc), and P47-67 (Sco1 and Lrpprc). (C) Western blot 
analysis of SCO1, CTR1, and COX II abundance in control (143B) and rho0 cells. Porin and Tubulin 
were used as loading controls for mitochondrial content and total protein respectively. (For B and C) 
Arrow represents the mature glycosylated form of CTR1, while the asterisk represents the truncated 
form of the protein. 
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4.1.3.2 Sco1 null MEFs are copper deficient owing to enhanced proteasomal degradation of 
CTR1 
We next wanted to determine whether the observed change in CTR1 abundance was caused by 
a decrease in protein synthesis or an increase in the rate of protein degradation. Ctr1 mRNA transcript 
levels in the liver of the Sco1livliv mice were unchanged in our genome-wide microarray RNA 
expression analysis (data not shown) and in our semi-quantitative, reverse-transcriptase PCR 
experiments (Figure 4.7A), suggesting that adequate mRNA existed to support protein synthesis. The 
lack of change in Ctr1 transcript levels was in marked contrast to the increase and decrease, 
respectively, in the mRNA levels of metallothionein 1 (Mt1) and the solute carrier family protein 
Slc41a2 (Figure 4.7A), which mirrored the changes in gene expression we observed in our microarray 
analysis. To consider the potential contribution of active CTR1 degradation, we first generated Sco1 
knockout mouse embryonic fibroblasts (MEFs). Successful excision at the Sco1 locus and absence of 
SCO1 protein was confirmed by PCR genotyping (Figure 4.7B) and Western blot analysis (Figure 
4.7C), respectively. Phenocopying the Sco1 knockout livers, Sco1 knockout MEFs had a reduction in 
the abundance of COX IV (Figure 4.7C), a severe copper deficiency (Figure 4.7F) and a decrease in 
the abundance of CTR1 (Figure 4.7D). CTR1 levels were rescued by overexpressing a Sco1 cDNA, 
while CTR1 overexpression only led to the accumulation of the truncated form of the protein (Figure 
4.7E). Consistent with these observations, the combined copper and COX deficiency was 
complemented by SCO1 but not CTR1 overexpression (Figure 4.7F). To further confirm that CTR1 
is preferentially degraded in the absence of Sco1 expression, we treated cells with the proteasomal 
inhibitor MG132 and found that it fully restored CTR1 levels in Sco1 knockout MEFs (Figure 
4.8A,B).  
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Figure 4.7: Deletion of Sco1 in mouse embryonic fibroblasts results in a decrease of CTR1 
abundance 
(A) Semi-quantitative RT-PCR analysis of metallothionein 1 (MT1), solute carrier family 41 member 
A2 (SLC41A2), and CTR1 mRNA transcript levels from livers of wild-type (Control) and liver-
specific Sco1 knockout (Sco1liv/liv) mice at P27. GAPDH was used as a loading control. (B) PCR 
genotyping of Sco1 gene in both control (untreated) or Sco1 knockout (treated with 0.5 μM purified 
CRE recombinase) MEFs determining presence of floxed (top) or deleted (bottom) second exon. (C) 
Western blot analysis of SCO1 and COX IV abundance in control (left) and Sco1 knockout (right) 
MEFs. SD70 was used as a loading control. (D) Western blot analysis of ATP7A, CTR1, and SCO1 
in both control (flox) and Sco1 knockout (KO-1-4) MEFs. SD70 is used as a loading control. (E) 
Western blot analysis of ATP7A, CTR1, SCO1, COX I, and COX IV in control (flox) and Sco1 
knockout (KO-5) MEFs either untreated, or overexpressing SCO1 or CTR1. Tubulin was used as a 
loading control. (For D and E) Arrow represents the mature glycosylated form of CTR1, while the 
asterisk represents the truncated form of the protein. (F) Total cytochrome c oxidase activity (black) 
and copper levels (white) in Sco1 knockout MEFs either untreated or overexpressing SCO1 or CTR1. 
Data are expressed as percentage of control MEFs. (n=4 for each measurement). ND = Not 
determined. 
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Figure 4.8: CTR1 abundance in MEFs is rescued by the proteosome inhibitor MG132 
(A) Western blot analysis of ATP7A and CTR1 abundance in control (flox) and Sco1 knockout MEFs 
both untreated and treated with 40 μM MG132. Arrow represents the mature glycosylated form of 
CTR1, while the asterisks represents the truncated form of the protein. Tubulin is used as a loading 
control. (B) Immunofluorescence analysis of CTR1 (green) expression and localization in control 
(flox) and Sco1 knockout (KO-5) treated with DMSO or MG132. Wheat germ agglutinin (red) is used 
as a plasma membrane marker. Co-staining signal in overlay is shown in yellow. 
47 
 
 
4.2 The role of SCO1 in maintaining cellular copper homeostasis in the murine heart 
4.2.1 Physiological characterization of Sco1hrt/hrt mice 
4.2.1.1 Validation of heart-specific Sco1 deletion 
Following the characterization of Sco1liv/liv mice, we next turned our attention to examining the 
role of SCO1 in the murine heart. We began by using an identical breeding strategy to that described 
in Section 4.1.1.1 and a transgenic line in which Cre recombinase expression is under the control of 
thea-myosin heavy chain promotor (αMHC) to generate a heart-specific Sco1 knockout mouse, 
herein referred to as Sco1hrt/hrt mice. Sco1hrt/hrt mice were viable and observed at the expected 
Mendelian frequencies (data not shown). Successful heart-specific deletion of the second exon of Sco1 
was verified using a three-primer PCR method (Figure 4.9A), and reduced SCO1 protein expression 
in the heart was confirmed as early as embryonic day 15 (E15) by Western blot analysis (Figure 4.9B). 
 
4.2.1.2 Heart-specific deletion of Sco1 is lethal with mice exhibiting left ventricular dilation and 
cardiomyocyte vacuolization 
Excision of the Sco1 alleles in the developing heart of Sco1hrt/hrt mice proved to be extremely 
severe. None of the Sco1hrt/hrt mice survived beyond P2 (Figure 4.9C), despite having the same body 
weight as their wild-type littermates (Figure 4.9D). To determine the cause of the observed perinatal 
lethality, we examined the heart of Sco1hrt/hrt mice histologically. Sco1 knockout hearts were 
misshapen and exhibited an enlarged left ventricle, characteristic of a dilated cardiomyopathy (Figure 
4.9E). Further characteristics of pathological cardiomyocyte dysfunction were observed upon 
hematoxylin and eosin (H&E) staining, including the enlargement of the cardiomyocytes as well as a 
distinct vacuolization (Figure 4.9F) in the absence any significant fibrosis (data not shown). 
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Figure 4.9: Deletion of Sco1 in the heart is lethal and presents with dilated cardiomyopathy 
(A) PCR analysis of the Sco1 gene determining presence of a floxed (415 bp) or deleted (379 bp) 
second exon in various tissues (H= Heart, B= Brain, L= Liver, K= Kidney, Sp= Spleen) in both 
wild-type (Controls) and heart-specific knockout mice (Sco1liv/liv) at P1. Top represents two primer 
PCR conditions to individually amplify the deleted allele. Bottom represents three primer PCR 
conditions to amplify both floxed and deleted alleles. (B) Western blot analysis of SCO1 and COX 
IV abundance in wild-type (Controls) and heart-specific Sco1 knockout (Sco1hrt/hrt) mice at E15, 
E17, and P1. GAPDH is used as a loading control. Multiple images for SCO1 represent a long and 
short exposure times. (C) Kaplan-Meier survival curve of wildtype (black, Controls, n=40) and 
heart-specific Sco1 knockout mice (grey, Sco1hrt/hrt, n=15). (D) Body weight (g) of wild-type 
(Controls) and heart-specific Sco1 knockout (Sco1hrt/hrt) mice at P1. (n= 6 for each genotype). (E) 
Hematoxylin and Eosin stained sections of hearts from wild-type (Control, left) and heart-specific 
Sco1 knockout (Sco1hrt/hrt, left) mice at P1. LV stands for left ventricle. Scale bar represents 500 µm. 
(F) 20X magnification of H&E stained sections of hearts from wild-type (Control, left) and heart-
specific Sco1 knockout (Sco1hrt/hrt, right) mice from panel D. Scale bar represents 50 µm. 
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4.2.2 Molecular characterization of Sco1hrt/hrt mice 
4.2.2.1 Sco1 knockout hearts exhibit a severe, isolated COX deficiency  
To determine the cause of the cardiomyopathy observed in the Sco1hrt/hrt mice we further 
examined the molecular phenotype of these hearts. Hearts from Sco1hrt/hrt mice had a severe COX 
deficiency at the level of enzymatic activity (Figure 4.10A), abundance of the structural subunit 
COXIV (Figure 4.10B) and the amount of fully assembled holoenzyme (Figure 4.10C). Unlike the 
Sco1 knockout liver, the hearts from Sco1hrt/hrt mice did not have an increase in mitochondrial content, 
as the activity of CS remained unchanged from wild-type littermates (Figure 4.10A).  
 
4.2.2.2 Sco1 knockout hearts have a modest copper deficiency that is not caused by a change in 
CTR1 abundance  
In addition to the COX deficiency, Sco1 knockout hearts had a significant decrease in total 
superoxide dismutase activity (Figure 4.10A) that was specific to the copper-dependent SOD1 form 
of the enzyme, as the levels of cyanide resistant Mn-SOD2 remained unaffected (Figure 4.10D). The 
deficiency in SOD1 suggested that deletion of Sco1 in the heart may result in a global copper 
deficiency. While Sco1 knockout hearts exhibited a statistically significant decrease in total copper 
levels (Figure 4.11A), it was modest with respect to the fold change. Similar to the Sco1liv/liv mice, the 
abundance of the copper exporter ATP7A was unchanged in Sco1 knockout hearts (Figure 4.11B). In 
contrast, however, CTR1 abundance was unaffected by lack of Sco1 expression in cardiomyocytes 
(Figure 4.11B), and the abundance of CCS was unchanged (Figure 4.11B). This suggests that loss of 
SCO1 function affected the copper sensing and import machinery in a tissue-specific manner. 
 
4.2.2.3 The livers of Sco1hrt/hrt mice have a significant copper deficiency and a decrease in CTR1 
abundance  
 Interestingly, the livers of Sco1hrt/hrt mice had a comparable copper deficiency to the hearts 
lacking Sco1 expression (Figure 4.11A), and a decrease in the abundance of CTR1 (Figure 4.11C). 
Even though this finding is reminiscent of the copper deficiency phenotype observed in the Sco1 
knockout liver, the decrease in the copper content of the livers of Sco1hrt/hrt mice did affect the activity 
of COX or SOD1 (Figure 4.11D) or the abundance of COX IV (Figure 4.11E). Copper levels in all 
other somatic tissues and plasma of Sco1hrt/hrt mice were unchanged when compared to wild-type 
littermates (Figure 4.11F). 
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Figure 4.10: Deletion of Sco1 in the heart causes an isolated COX deficiency 
(A) Specific activities of cytochrome c oxidase (COX, black, n= 3), total super oxide dismutase (SOD, 
white, n= 6), and citrate synthase (CS, grey, n= 3) in the hearts from P1 heart-specific Sco1 knockout 
(Sco1hrt/hrt) mice expressed as a percentage of wild-type litter mates. (B) Western blot analysis of the 
abundance of representative subunits from complexes I-V of electron transport chain in hearts from 
wild-type (Control) and heart-specific Sco1 knockout (Sco1hrt/hrt) mice at P1. GAPDH is used as a 
loading control. (C) Blue Native PAGE analysis of the abundance of complexes I-V of electron 
transport chain in wild-type (Control) and heart-specific Sco1 knockout (Sco1hrt/hrt) mice at P1. (D) 
Specific activity of the cyanide-resistant Mn-SOD2 (mU/mg protein) in wild-type (Control, black) 
and heart-specific Sco1 knockout (Sco1hrt/hrt, white) mice at P1. (n= 3 for both genotypes). 
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Figure 4.11: Deletion of Sco1 in the heart causes a mild copper deficiency 
(A) Total copper levels in the hearts and livers from heart-specific Sco1 knockout (Sco1hrt/hrt) mice at 
P1 expressed as a percentage of wild-type littermates. (n= 3 for each tissue). (B) Western blot analysis 
of ATP7A, CCS, and CTR1 abundance in hearts from wild-type (Control) and heart-specific Sco1 
knockout (Sco1hrt/hrt) mice at P1. Hearts from P7 wild-type (Control) and heart-specific Ctr1 knockout 
(Ctr1hrt/hrt) mice were used as a control to identify specific CTR1 signal. MEFs treated with scrambled 
(Ccswt) and siRNA targeting CCS (CcssiRNA) were used as controls for confirming specific CCS signal 
represented by unfilled arrow. GAPDH is used as a loading control. (C) Western blot analysis of 
ATP7A, and CTR1 abundance in livers from wild-type (Control) and heart-specific Sco1 knockout 
(Sco1hrt/hrt) mice at P1. GAPDH is used as a loading control. (For B and C) Arrow represents the 
mature glycosylated form of CTR1, while the asterisk represents the truncated form of the protein. 
(D) Specific activities of cytochrome c oxidase (COX, left), total super oxide dismutase (SOD, 
middle), and citrate synthase (CS, right) in the livers (grey) and brains (hatched) from P1 heart-specific 
Sco1 knockout (Sco1hrt/hrt) mice expressed as a percentage of wild-type littermates. (n= 4 for each 
enzyme and tissue). (E) Western blot analysis of the abundance of representative subunits from 
complexes I-V of electron transport chain in livers from wild-type (Control) and heart-specific Sco1 
knockout (Sco1hrt/hrt) mice at P1. GAPDH is used as a loading control. (F) Total copper levels (µg 
Cu/mg Sulphur [S]) in brain (left), kidney (middle), and plasma (right) from wild-type (Control) and 
heart-specific Sco1 knockout (Sco1hrt/hrt) mice at P1. 
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4.2.3 Physiological characterization of Sco1stm/stm mice 
4.2.3.1 Validation of striated muscle-specific Sco1 deletion 
 As the perinatal lethality in the Sco1hrt/hrt mice precluded more meaningful investigation of the 
mechanisms underling the copper deficiency in the Sco1 knockout heart, we generated a second mouse 
model in which Sco1 was deleted in all striated muscle. Striated muscle-specific knockout mice, 
hereafter referred to as Sco1stm/stm mice, were generated by crossing Sco1flox/flox mice with a transgenic 
mouse expressing Cre recombinase under the control of the muscle-specific creatine kinase (MM-CK) 
promoter (see 4.1.1.1 and 4.2.1.1). Sco1stm/stm mice were viable and observed at the expected 
Mendelian frequencies (data not shown). Sco1stm/stm mice had a longer lifespan than the Sco1hrt/hrt 
mice; however, the deletion of Sco1 was ultimately lethal and Sco1stm/stm mice had a median lifespan 
of 99 days (Figure 4.12A). Hearts of Sco1stm/stm mice exhibited expression of Sco1 for significantly 
longer than the hearts of Sco1hrt/hrt mice as we were able to detect small amounts of the protein within 
the linear range of exposure up until P6 (Figure 4.12B). Deletion of the Sco1 locus was restricted to 
the striated muscle as determined by PCR amplification of the genomic DNA from a number of 
peripheral tissues (Figure 4.12C). 
 
4.2.3.2 Sco1stm/stm mice develop severe cardiomyopathy with significant fibrosis and enlarged 
cardiomyocytes 
 The increased lifespan of the Sco1stm/stm mice allowed us to investigate the effect of Sco1 ablation 
on cardiac function in the adult mouse. Although there was no difference between the body weight of 
the Sco1stm/stm mice and their wild-type littermates at P90 (Figure 4.12D), the hearts of Sco1stm/stm mice 
were significantly larger and weighed roughly 2 fold more (Figure 4.12E,F). Histological analysis of 
the hearts of Sco1stm/stm mice showed common signs of cardiac hypertrophy such as enlargement and 
vacuolization of the cardiomyocytes, as well as the presence of significant fibrosis within the cardiac 
tissue (Figure 4.12G). Consistent with the idea that the hearts of Sco1stm/stm mice develop a 
cardiomyopathy, we observed the upregulation of genes known to be biomarkers of fetal cardiac 
remodeling such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and α-skeletal 
actin (α-SA), and the downregulation of the calcium pump SERCA2a (Figure 4.12H). 
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Figure 4.12: Deletion of Sco1 in the striated muscle is lethal and presents with cardiomyopathy 
(A) Kaplan-Meier survival curve of wild-type (black, Controls, n=22) and striated muscle-specific 
Sco1 knockout (grey, Sco1stm/stm, n=18) mice. (B) Western blot analysis of SCO1 and COX IV 
abundance in wild-type (Controls) and striated muscle-specific Sco1 knockout (Sco1stm/stm) mice at 
E17, P1, P3, and P9. GAPDH is used as a loading control. Multiple images for SCO1 represent a long 
and short exposure times. (C) PCR analysis of the Sco1 gene determining presence of a floxed (415 
bp) or deleted (379 bp) second exon in various tissues (B= Brain, H= Heart, K= Kidney, L= Liver, 
So= Soleus, Sp= Spleen) from both wild-type (Controls) and striated muscle-specific Sco1 knockout 
(Sco1stm/stm) mice at P1. Top represents two primer PCR conditions to individually amplify the deleted 
allele. Bottom represents three primer PCR conditions to amplify both floxed and deleted alleles. (D) 
Body weight (g) of wild-type (Controls) and striated muscle-specific Sco1 knockout (Sco1stm/stm) mice 
at P90. (n= 6 for each genotype). (E) Hearts from wild-type (Control, left) and striated muscle-specific 
Sco1 knockout (Sco1stm/stm, right) mice at P90. (F) Ratio of heart weight (mg) to body weight (g) for 
wild-type (Controls) and striated muscle-specific Sco1 knockout (Sco1stm/stm) mice at P90. (n= 7 for 
each genotype). (G) 20X magnification of Hematoxylin and Eosin (top) and Masson’s trichrome 
(bottom) stained sections of hearts from both wild-type (Control, left) and striated muscle-specific 
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Sco1 knockout (Sco1stm/stm, right) mice at P90. Scale bar represents 50 μm. (H) Semi-quantitative RT-
PCR analysis of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), α-skeletal actin 
(αSA), sarco/endoplasmic reticulum Ca2+-ATPase 2a (SERCA2a), and metallothionein 1 (MT1) 
mRNA transcript levels in livers from wild-type (Controls) and striated muscle-specific Sco1 
knockout (Sco1stm/stm) mice at P90. GAPDH was used as a loading control. 
 
4.2.3.3 Echocardiogram of Sco1stm/stm hearts shows dilation of the left ventricle 
 To further investigate the observed cardiomyopathy, we performed echocardiography on the 
hearts of Sco1stm/stm and wild-type mice at P60 and P90. P60 Sco1stm/stm mice did not have any 
significant differences in heart function or ventricular size (data not shown); however, by P90 
Sco1stm/stm mice displayed signs of a dilated cardiomyopathy including a dilated left ventricle which 
significantly impaired contraction (Figure 4.13A). Quantification of the echocardiographic data 
further revealed that the Sco1 knockout hearts had significantly lower fractional shortening and 
ejection fractions, confirming that ventricular dilation adversely affected cardiac dysfunction (Figure 
4.13B).   
 
Figure 4.13: Deletion of Sco1 in the striated muscle causes dilated cardiomyopathy 
(A) Echocardiogram image of left ventricle from wild-type (Control) and striated muscle-specific 
Sco1 knockout (Sco1stm/stm) mice at P90. Scale bar represents 0.1 sec. (B) Quantification of cardiac 
output parameters: left ventricular internal diameter from systole (LVIDs) (top left) and diastole 
(LVIDd) (top right), ejection fraction (bottom left), and fractional shortening (bottom right) in wild-
type (Control, white) and striated muscle-specific Sco1 knockout (Sco1stm/stm, grey) mice at P90 
determined by echocardiogram. (n= 4 for each genotype and measurement). 
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4.2.4 Molecular characterization of Sco1stm/stm mice 
4.2.4.1 Sco1stm/stm mice have an isolated COX deficiency combined with a deficiency in SOD1 
activity 
 Like the other tissue-specific Sco1 knockout mouse models we characterized, the hearts of 
Sco1stm/stm mice exhibited a severe deficiency in the enzymatic activity of COX and the copper-
dependent form of SOD1 (Figure 4.14A,B). Native and denaturing polyacrylamide gel electrophoresis 
analyses confirmed that the abundance of all the other complexes of OXPHOS was unaffected and 
that the deletion of Sco1 in the heart resulted in an isolated COX deficiency (Figure 4.14C,D). The 
activity of CS was also unchanged in the hearts of Sco1stm/stm mice (Figure 4.14A) which, when 
combined with the lack of a change in other OXPHOS complexes, suggests that mitochondrial content 
remained constant.  
 
4.2.4.2 Sco1stm/stm mice have a severe copper deficiency that is not the result of reduced CTR1 
abundance 
 The severe, combined COX and SOD1 deficiency suggested that the Sco1 knockout heart was 
severely copper deficient. Consistent with this idea, we found that copper levels in the hearts of 
Sco1stm/stm mice were significantly lower relative to the hearts of their wild-type counterparts (Figure 
4.14E). This copper deficiency occurred without changes in iron or zinc levels (Figure 4.14E) and was 
specific to the heart as the copper levels in the liver and brain were unaltered (Figure 4.14F). 
Interestingly, copper-deficient hearts of P90 Sco1stm/stm mice had normal levels of the copper importer 
CTR1 and a modest increase in ATP7A abundance (Figure 4.14G). These data corroborate the 
observations made in the Sco1hrt/hrt mice and further suggest that the underlying mechanisms 
responsible for the copper deficiency in the absence of SCO1 are different in the heart and liver. 
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Figure 4.14: Deletion of Sco1 in the striated muscle causes an isolated COX deficiency 
(A) Specific activities of cytochrome c oxidase (COX, black), total super oxide dismutase (SOD, 
white), and citrate synthase (CS, grey) in the hearts from P90 striated muscle-specific Sco1 knockout 
(Sco1stm/stm) mice expressed as a percentage of wild-type litter mates. (n= 6 for all genotypes and 
enzymes). (B) Specific activity of the cyanide-resistant Mn-SOD2 (mU/mg protein) in wild-type 
(Control, white) and striated muscle-specific Sco1 knockout (Sco1stm/stm, grey) mice at P90. (n= 3 for 
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both genotypes). (C) Blue Native PAGE analysis of the abundance of complexes I-V of electron 
transport chain in wild-type (Control) and striated muscle-specific Sco1 knockout (Sco1stm/stm) mice 
at P90. (D) Western blot analysis of the abundance of representative subunits from complexes I-V of 
electron transport chain in hearts from wild-type (Control) and striated muscle-specific Sco1 knockout 
(Sco1stm/stm) mice at P90. GAPDH is used as a loading control. (E) Total levels of copper (white), iron 
(grey), and zinc (black) in hearts from striated muscle-specific Sco1 knockout mice at P90 expressed 
as a percentage of wild-type littermates. (n= 3 for each genotype and measurement). (F) Total levels 
of copper (black), iron (white), and zinc (grey) in livers and brains from striated muscle-specific Sco1 
knockout mice at P90 expressed as a percentage of wild-type littermates. (n= 3 for each genotype, 
tissue, and measurement). (G) Western blot analysis of ATP7A, CTR1, CCS, SCO1, and COX IV 
abundance in hearts from wild-type (Control) and striated muscle-specific Sco1 knockout (Sco1stm/stm) 
mice at P90. GAPDH is used as a loading control. Arrow represents the mature glycosylated form of 
CTR1, while the asterisk represents the truncated form of the protein. 
 
4.2.4.3 The combined COX and copper deficiencies progressively worsen with age 
 Given that the hearts of P90 Sco1stm/stm mice are severely affected and the animals are in an 
advanced disease state, we characterized the effect of deleting Sco1 in the heart of this mouse model 
on COX assembly and copper homeostasis at earlier time points. The hearts of Sco1stm/stm mice 
exhibited a mild COX deficiency at P18 in absence of any changes in total cellular copper levels 
(Figure 4.15A,B). However, both COX activity and total copper content progressively declined with 
time and a severe, combined deficiency was observed by P60 (Figure 4.15A,B). Despite a marked 
copper deficiency at P30 and P60, ATP7A levels were unchanged (Figure 4.15C) suggesting that the 
increase in its abundance at P90 occurs well after the onset of the copper deficiency. Remarkably and 
in marked contrast to the Sco1liv/liv phenotype (Figure 4.5A), CTR1 abundance was higher in the 
copper-deficient hearts of Sco1stm/stm mice at P30 and P60 (Figure 4.15C). The abundance of the 
cellular copper biomarker CCS was also unchanged in the hearts of these mice (Figure 4.15C). 
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Figure 4.15: Copper and COX deficiencies in striated muscle-specific Sco1 knockout mice get 
progressively worse over time 
(A) Specific activities of cytochrome c oxidase (COX), total super oxide dismutase (Total SOD), and 
citrate synthase (CS) in the hearts from P18 (white), P30 (black), and P60 (grey) striated muscle-
specific Sco1 knockout (Sco1stm/stm) mice expressed as a percentage of wild-type littermates. (n= 3 for 
all genotypes, timepoints and enzymes). (B) Total levels of copper, iron, and zinc in hearts from P18 
(white), P30 (black), and P60 (grey) striated muscle-specific Sco1 knockout (Sco1stm/stm) mice 
expressed as a percentage of wild-type littermates. (n= 3 for all genotypes, timepoints and metals). 
(C) Western blot analysis of ATP7A, CTR1, CCS, SCO1, and COX IV abundance in hearts from P18, 
P30, and P60 wild-type (Controls) and striated muscle-specific Sco1 knockout (Sco1stm/stm) mice. 
GAPDH is used as a loading control. Arrow represents the mature glycosylated form of CTR1, while 
the asterisk represents the truncated form of the protein. 
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4.2.4.4 The copper deficiency in Sco1stm/stm hearts is caused by the mislocalization of CTR1 
 The absence of changes in the abundance of CTR1 led us to consider whether deletion of Sco1 
in the heart leads to its mislocalization. We chose to examine the hearts of Sco1stm/stm mice at P60, 
because the copper deficiency is significant but cardiac function remains normal. Mirroring a prior 
study (Kuo et al., 2006), the hearts of wild-type mice had positive staining for CTR1 within the 
intercalated discs of the cardiomyocytes, with the most intense staining co-localizing with the plasma 
membrane marker Na+/K+ ATPase. (Figure 4.16A,B). In contrast, the hearts of Sco1stm/stm mice had 
intense intracellular CTR1 staining (Figure 4.16A,B). To determine whether the intracellular CTR1 
in the Sco1 knockout heart reflected its internalization from the plasma membrane or altered 
trafficking, we examined its co-localization with several intracellular markers. We found that the 
internalized CTR1 signal significantly overlaid with the endosomal marker Rab5, suggesting that 
intracellular CTR1 was located in endosomes (Figure 4.17A,B). However, intracellular CTR1 did not 
co-localize with either the early endosomal marker EEA1 or the late endosomal/lysosomal marker 
LAMP1 (Figure 4.18,AB). 
 
4.2.5 Characterization of a Sco1G115S/G115S knock-in mouse 
To further investigate how altered SCO1 function effects changes in CTR1 localization in the 
heart, we decided to generate Sco1 knock-in mice harbouring the homologous glycine to serine 
substitution that causes a fatal hypertrophic cardiomyopathy in humans (Stiburek et al., 2009). The 
codon substitution causing this mutation (GGG-AGC) was successfully confirmed by real-time qPCR 
using probes specific to the wild-type or mutated region within the 3rd exon of Sco1 (data not shown). 
Like the phenotypes observed in the Sco1 knockout hearts, the hearts of Sco1G115S/G115S mice had both 
a severe COX and copper deficiency (Figure 4.19A,B), and the copper deficiency was not caused by 
changes in the abundance of the copper transporters ATP7A or CTR1 (Figure 4.19A). Finally, CTR1 
was similarly mislocalized in the cardiomyocytes of the Sco1G115S/G115S mice, with focal intracellular 
staining rather than localization to the intercalated discs (Figure 4.20A,B). 
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Figure 4.16: Deletion of Sco1 in the striated muscle causes the mislocalization of CTR1 in 
cardiomyocytes 
(A) Immunofluorescence analysis of CTR1 (green) localization in hearts of wild-type (Control, top) 
and striated muscle-specific Sco1 knockout (Sco1stm/stm, bottom) mice at P60. Na+/K+ ATPase (red) 
was used as a positive control for plasma membrane. Images were taken at 40X and scale bar 
represents 20 μm. Co-stained signal in overlay is shown in yellow. Inset represents magnified image 
of region of interest (white box). (B) Enlarged image of region of interest from overlay in A. 
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Figure 4.17: Mislocalized CTR1 in the hearts of striated muscle-specific mice co-localizes with 
Rab5 
(A) Immunofluorescence analysis of co-localization between CTR1 (green) and endosomal marker 
Rab5 (red) in hearts of wild-type (Control, top) and striated muscle-specific Sco1 knockout 
(Sco1stm/stm, bottom) mice at P60. Images were taken at 40X and scale bar represents 20 μm. Co-
stained signal in overlay is shown in yellow. Inset represents magnified image of region of interest 
(white box). Images were taken at 40X and scale bar represents 20 μm. Co-stained signals in overlay 
is shown in pink, yellow, and white. Inset represents magnified image of region of interest (white 
box). (B) Enlarged image of region of interest from overlay in A. 
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Figure 4.18: Mislocalized CTR1 does not co-localize with EEA1 or LAMP1 
(A) Immunofluorescence analysis of co-localization between CTR1 (green), early endosomal marker 
EEA1 (blue), and late endosomal/lysosomal marker LAMP1 (red) in hearts of wild-type (Control, 
top) and striated muscle-specific Sco1 knockout (Sco1stm/stm, bottom) mice at P60. Images were taken 
at 40X and scale bar represents 20 μm. Co-stained signals in overlay is shown in pink, yellow, and 
white. Inset represents magnified image of region of interest (white box). (B) Enlarged image of region 
of interest from overlay in A. 
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Figure 4.19: Mice harboring G115S homozygous mutation in Sco1 phenocopy the striated 
muscle-specific Sco1 knockout mice 
(A) Western blot analysis of ATP7A, CTR1, CCS, SCO1, and COX IV abundance in hearts from 
wild-type (Control) and G115S Sco1 knock-in (Sco1G11S/G115S) mice at P120. GAPDH is used as a 
loading control. Arrow represents the mature glycosylated form of CTR1, while the asterisk represents 
the truncated form of the protein. (B) Total copper levels (µg/mg Sulphur [S]) in hearts from wild-
type (Control, white) and G115S Sco1 knock-in (Sco1G11S/G115S, grey) mice at P120. (n= 3 for each 
genotype). 
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Figure 4.20: CTR1 in G115S homozygous knock-in mice is mislocalized from plasma membrane 
(A) Immunofluorescence analysis of CTR1 (green) localization in hearts of wild-type (Control, top) 
and G115S Sco1 knock-in (Sco1G11S/G115S, bottom) mice at P120. Na+/K+ ATPase (red) was used as a 
positive control for plasma membrane. Images were taken at 40X and scale bar represents 20 μm. Co-
stained signal in overlay is shown in yellow. Inset represents magnified image of region of interest 
(white box). (B) Enlarged image of region of interest from overlay in A. 
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5. Discussion 
As SCO1 and SCO2 are both known COX assembly factors with essential roles in the 
metallation of the CuA site of COX2, it is unsurprising that patients harbouring pathogenic mutations 
in either gene present with a severe COX deficiency in affected tissues. More surprising, however, is 
that affected SCO patient tissues also exhibit a significant reduction in total copper levels. How and 
why the disrupted function of two copper-binding proteins that are physically localized to the inner 
membrane of the mitochondrion has such a pronounced effect on copper homeostasis at the whole 
cell level remains a mystery. An understanding of how the organelle fits into the regulatory framework 
that governs copper homeostasis is challenged by the fact that little to nothing is known about the 
mechanisms cells and tissues employ to modulate the levels and bioavailabity of the metal ion. To 
begin to address this knowledge gap, we generated multiple mouse models in which SCO1 function 
was ablated or altered in a tissue-specific manner and used a number of approaches to characterize the 
relevant tissues at a biochemical, molecular, genetic and elemental level. We restricted our focus to 
the importance of SCO1 function to copper homeostasis in the liver and heart as these are two of the 
most severely affected tissues in SCO1 patients that have been described to date.  
All of our Sco1 mouse models displayed profound, tissue-specific phenotypes that were 
ultimately lethal. Sco1liv/liv mice presented with a severe hepatopathy, characterized by hepatomegaly, 
marked steatosis, and release of enzymes into the serum indicative of liver failure. Sco1 knockout 
hearts in both the heart- and striated muscle-specific models were markedly dilated with 
cardiomyocytes exhibiting altered architecture. Deletion of Sco1 in the liver, heart or striated muscle 
was lethal arguing that, like in humans, SCO1 function is also essential to COX assembly and copper 
homeostasis in the mouse. While it is tempting to speculate that the different lifespan of each model 
reflects the relative importance of SCO1 to the integrity of these two pathways in each tissue, there 
are significant differences between models with respect to when the Cre transgene is turned on during 
development. In fact, it is likely that the early lethality observed in the Sco1hrt/hrt mice compared to 
the Sco1stm/stm mice is caused by the almost complete absence of SCO1 protein in the hearts of 
Sco1hrt/hrt mice as early as E15. Expression of the Cre transgene later on in heart development in the 
Sco1stm/stm mice allowed for wild-type levels of SCO1 until P1 with appreciable amounts of protein 
remaining until P9, suggesting that perhaps there is a perinatal window when SCO1 expression in the 
heart is absolutely critical for survival. Why the Sco1stm/stm mice continued to live for several months 
without Sco1 expression in the cardiomyocytes is unknown. One possibility, supported by the 
Sco1stm/stm enzymology data, is that the half-life of the COX holoenzyme is relatively long in juvenile 
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and adult mice and sufficient residual COX activity remained to support normal heart function. 
Consistent with this idea, echocardiography revealed that heart function in Sco1stm/stm mice was 
equivalent to that of wild-type littermates at P60.  
Our Sco1 knockout and knockin mouse models exhibited a combined COX and copper 
deficiency and therefore phenocopied affected tissues of SCO1 patients. Firstly, both the livers of 
Sco1liv/liv mice and hearts of Sco1stm/stm mice had significant, isolated COX deficiencies. Residual 
enzyme activity in Sco1 knockout livers was comparable to that of fibroblasts from the SCO1 patient 
who presented with a severe hepatopathy (Leary et al., 2007), and that of Sco1 knockout hearts was 
similar to the muscle of the SCO1 patient with a hypertrophic cardiomyopathy (Stiburek et al., 2009). 
Consistent with the reduction in enzymatic activity, Sco1 knockout tissues also had reduced levels of 
both the COX holoenzyme and the structural subunit COX IV. Both the livers of Sco1liv/liv mice and 
the hearts of Sco1stm/stm mice also had a severe copper deficiency. The hearts of Sco1G115S/G115S knock-
in mice mirrored those of the Sco1stm/stm mice, suggesting that mitochondrial signalling crucial to the 
regulation of copper homeostasis is similarly perturbed in animals expressing an allelic variant of 
Sco1 that is pathogenic in humans. Taken together, these data suggest that these mouse models provide 
a robust avenue with which to explore the underlying etiology of human diseases caused by mutations 
in SCO1.  
Interestingly, the livers of Sco1liv/liv mice further phenocopied the human patient condition in 
that the mitochondrial copper pool was preserved in spite of the severe global copper deficiency. 
SCO1 and SCO2 patient fibroblasts and liver also prioritize the preservation of their organelle copper 
pool (Dodani et al., 2010). These and other findings suggest that there may in fact be a hierarchy of 
copper homeostasis within the cell, and that delivery of copper to various organelles and, by extension, 
cuproproteins is prioritized in both healthy and disease states. The ability of the cell and even the 
organism to preferentially route copper to specific proteins or compartments has been observed in 
other model systems. When the zebrafish embryo is challenged with a copper deficiency, it routes 
copper to the pathways of highest priority in an effort to preserve the developmental program 
(Mendelsohn et al., 2006). The single-celled green algae Chlamydomonas reinhardtii preferentially 
shuttles copper to mitochondria at the expense of chloroplasts under copper-limiting conditions 
(Merchant and Bogorad, 1986). Finally, by altering the levels of the mitochondrial protein CMC1 one 
can shift the relative distribution of copper from IMS-localized SOD1 to COX (Horn et al., 2008), 
suggesting that even within an organelle signalling pathways exist to tightly control routing of the 
metal ion. How these signalling pathways function coordinately to regulate copper homeostasis at the 
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cellular level and how mitochondrial signalling contributes to this regulatory framework will be 
important questions to address in the future. 
One of the major differences between our mouse models and SCO1 patient fibroblasts is that 
mutations that alter SCO1 function have fundamentally different consequences on the abundance and 
localization of proteins involved in copper transport. In SCO1 and SCO2 patient fibroblasts the copper 
deficiency is caused by an increase in ATP7A-dependent copper export from the cells (Leary et al., 
2007; Leary et al., 2013), similar to the increases in ATP7A abundance driving the copper deficiency 
in our liver-specific Lrpprc knockout mice. In contrast, we only observed an increase in ATP7A 
abundance in our Sco1 models just prior to lethality, long after the copper deficiency was manifest. 
While ATP7A can effect changes in the rate of copper efflux without a change in its abundance (Petris 
et al., 1996), we did not investigate whether ATP7A or ATP7B localization were altered in tissues of 
interest. This choice reflects the profound changes we observed in both the abundance and localization 
of CTR1 in the Sco1 knockout livers and hearts and in the Sco1G115S/G115S knock-in heart, which 
suggest that the copper import machinery is predominantly affected in these murine cell types upon 
perturbing SCO1 function. The root cause of the unique effects on the export and import machinery 
observed in SCO1 patient fibroblasts relative to our mouse models is unknown. While it is admittedly 
difficult to directly compare results from a cell culture isolate to an organ in situ, it is also possible 
that distinct, cell-type specific effectors downstream of mitochondrial signalling dictate which arm of 
copper homeostasis is primarily affected by loss of SCO1 function.  
Multiple lines of evidence from each of our mouse models strongly suggest that SCO1 has a 
role in maintaining the correct localization and, in some cases, the abundance of CTR1. The livers of 
Sco1liv/liv mice had a mild but significant copper deficiency as early as P18, and there was evidence 
shortly thereafter of CTR1 internalization from the plasma membrane. As the copper deficiency 
worsened with time, CTR1 abundance also decreased and the protein was eventually undetectable 
immunologically. CTR1 levels were also reduced in copper-deficient Sco1 knockout MEFs and were 
rescued upon forced overexpression of SCO1 suggesting a direct role for the protein or the organelle 
in preserving cellular copper import competence. We determined that the decrease in CTR1 levels 
was due to the increased degradation of the protein, as Ctr1 mRNA transcript abundance was 
unaffected in the Sco1 knockout livers and CTR1 protein levels in Sco1 knockout MEFs were rescued 
by inhibiting the proteasome. Consistent with this idea, forced overexpression of a Ctr1 cDNA in Sco1 
knockout MEFs failed to increase the abundance of the mature, glycosylated CTR1 species. The 
degradation of CTR1 via the proteasome is an interesting result, as the canonical degradation pathway 
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of plasma membrane transporters typically occurs via endocytosis and eventual fusion of the resultant 
vesicles with lysosomes (MacGurn et al., 2012). It may be that the CTR1 protein is degraded through 
retrograde trafficking within the endoplasmic reticulum-associated degradation (ERAD) pathway, 
which has been found to digest some misfolded plasma membrane proteins in a proteasomal-
dependent manner (Vembar and Brodsky, 2008). However, recent findings indicate that the iron 
transporter ZIP14 is also turned over by the proteasome following its endocytosis in HEK293 cells 
(Zhao et al., 2014). Thus, there is a precedent in the literature that supports our model of proteasomal 
degradation of CTR1 upon loss of SCO1 function. Interestingly, the copper deficiency in the livers of 
Sco1hrt/hrt mice was also caused by a decrease in the total abundance of CTR1, which seems to support 
the possibility that hepatocytes regulate cellular copper through this mechanism. 
The cardiac copper deficiencies in our heart-specific Sco1 knockout mouse models and the 
Sco1G115S/G115S knock-in mouse were also caused by post-translational modifications of CTR1 that 
reduced copper import. Like other nutrient transporters (Doria-Medina et al., 1993; Kleber and Saffitz, 
2014), the majority of CTR1 in the wild-type heart was localized to the intercalated discs, at the cell-
cell junctions between individual cardiomyocytes. This localization pattern has previously been 
reported for CTR1 (Kuo et al., 2006), and presumably represents the most ideal mechanism for copper 
to be transported between cardiomyocytes that are not immediately adjacent to the vasculature. In 
contrast, the hearts of both the Sco1stm/stm and Sco1G115S/G115S mice displayed intense intracellular 
localization of CTR1 that was coincident with the early endosomal marker Rab5. This suggests that, 
like the liver, CTR1 was internalized from the plasma membrane in response to altered SCO1 function. 
However, CTR1 did not co-localize with another early endosomal marker, EEA1, or with the late 
endosomal/lysosomal marker LAMP1.  
The intracellular localization of CTR1 in the hearts of our Sco1stm/stm and Sco1G115S/G115S mice 
differs from an earlier report in the literature which found that internalized CTR1 co-localizes with 
Rab5, EEA1 and Rab7, all common markers for the early endosomal/recycling pathway (Clifford et 
al., 2016). These initial findings were made in cultured HEK293 cells in which mitochondrial 
signalling through SCO1 remained intact. However, it is plausible that the mechanisms that dictate 
sorting, trafficking and ultimately the fate of internalized CTR1 differ across cell types. The existence 
of such cell-type specific mechanisms is supported by the differences between our heart- and liver-
specific Sco1 mouse models with respect to CTR1 degradation. The exact function and significance 
of the Rab5-positive, EEA1-negative endosomes containing CTR1 in the Sco1stm/stm and 
Sco1G115S/G115S models remains unknown. It is possible that this subpopulation of endosomes is part 
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of a newly characterized, long-term recycling pathway containing the effectors APPL1 and APPL2 
rather than EEA1 (Kalaidzidis et al., 2015; Urbanska et al., 2011). Although this possibility has yet to 
be confirmed, the presence of internalized CTR1 within this alternative recycling pathway raises the 
intriguing possibility that the cardiomyocyte and hepatocyte use different strategies to dynamically 
regulate copper import. Why the heart appears to preferentially store CTR1 in a long-term recycling 
pathway while the liver chooses to degrade the protein may be explained by the general copper 
requirement of the two tissues in question. Heart- and liver-specific deletion of Ctr1 in mice has 
radically different consequences for animal viability. Deletion of Ctr1 in either the developing or adult 
heart results in an early onset, fatal hypertrophic cardiomyopathy (Kim et al., 2010), suggesting that 
in cardiomyocytes there is a continuous need for CTR1-dependent copper import. In contrast, liver-
specific Ctr1 knockout mice have a relatively mild copper deficiency and a normal lifespan. Under 
normal physiological conditions, copper concentrations in the liver are much higher than that of the 
heart, particularly during development where copper stores in the liver are exported into the blood 
stream to support the growth of peripheral organs. Although the localization of CTR1 at the plasma 
membrane increases dramatically with time in hepatocytes, suggesting that the murine liver becomes 
more of a copper uptake organ later in life, intra-hepatic levels of the metal ion reflect a dynamic 
equilibrium between copper export into the general circulation and inclusion in the bile for excretion. 
Therefore, the degradation of CTR1 in liver under copper replete conditions may make the most sense, 
as there is less of a need for rapid copper uptake compared to the heart, should exogenous copper 
levels drop. 
While it remains unclear why altered SCO1 function in cardiomyocytes led to mislocalization 
of the protein without its eventual degradation as we observed in the Sco1 knockout liver, it may be 
that each tissue expresses unique effectors downstream of the mitochondrial copper signalling 
pathway. Certainly, it appears the cellular copper sensing machinery is differentially affected in the 
livers of Sco1liv/liv mice when compared to the hearts of Sco1stm/stm or Sco1G115S/G115S mice. The 
abundance of CCS, the most reliable biomarker of intracellular copper levels (Lassi and Prohaska, 
2012), should increase in a copper-deficient state and decrease upon copper overload. However, CCS 
abundance decreases in the Sco1 knockout liver while it remains unchanged in the Sco1 transgenic 
heart, indicating that loss of SCO1 function in both model systems compromises the proper 
monitoring of cellular copper status. In fact, these findings argue that the liver of Sco1liv/liv mice is 
sensing a copper overload state during which the normal response is to rapidly turnover CTR1 (Petris 
et al., 2003). Why CCS levels remain unchanged in the copper-deficient Sco1 null G115S heart is 
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unclear, although the internalization of the bulk of the CTR1 pool suggests that the cardiomyocytes 
also sense that they are copper replete. The differences in CCS abundance between the Sco1 transgenic 
heart and liver may explain why CTR1 abundance only declined in the latter tissue, as the protein is 
known to be degraded under conditions of prolonged copper excess while it is only internalized under 
mild copper excess (Petris et al., 2003). 
The upregulation of the metallothionein 1 gene further supports the argument that the Sco1 null 
hepatocytes are sensing a state of copper overload, as this is a well established response to conditions 
of copper excess (Freedman et al., 1989; Fürst et al., 1988). Interestingly, an increase in the abundance 
of metallothionein would effectively exacerbate the copper deficiency because it would sequester the 
limiting amounts of bioavailable copper that remained in the cell. An increase in metallothionein 
expression is also observed in the livers of a mouse model of Wilson disease (Muchenditsi et al., 
2017). Due to the deletion of Atp7b and the resultant dysregulation of biliary copper export, these 
mice hyperaccumulate copper in their livers. Liver-specific Atp7b knockout mice also develop a 
significant hepatic steatosis and upregulate the expression of genes involved in lipid biosynthesis 
(Muchenditsi et al., 2017), responses we also observed in our liver-specific Sco1 knockout mice. 
Comparable compensatory responses in both the liver-specific Atp7b and liver-specific Sco1 knockout 
mice further support the idea that the Sco1 null hepatocyte is inappropriately sensing a state of copper 
overload and raise the possibility that the copper deficiency upon ablation of Sco1 expression in the 
liver may be driven initially by the copper export system. Such a scenario is consistent with a transient 
spike in bioavailable copper within the cytosol, which would then be predicted to cause the 
internalization and degradation of CTR1. Whether this initial response is accompanied by aberrant 
mitochondrial signaling that stimulates copper efflux via the secretory pathway or by redistribution of 
ATP7A/B remains unknown.  
Despite the modest copper deficiency in the hearts of Sco1hrt/hrt mice, we observed a significant 
copper deficiency in their livers pointing to the potential crosstalk between these two organs. A 
previous study of heart-specific Ctr1 knockout mice supports the idea that the heart communicates its 
copper status to the liver (Kim et al., 2010). In the Ctr1hrt/hrt mice, the deletion of Ctr1 in the heart 
with the same Cre driver we used to generate our Sco1hrt/hrt mouse results in a significant increase in 
CCS abundance, arguing that the cardiomyocytes are appropriately sensing a copper deficient state. 
This leads to a significant increase in ATP7A abundance in hepatocytes and an increased copper 
mobilization into the bloodstream, presumably in an effort to resupply the heart with copper. HepG2 
cells exposed to serum isolated from Ctr1hrt/hrt mice expressed significantly more ATP7A, arguing 
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that the heart secretes a soluble factor into the plasma to communicate with the liver. Although we 
saw a similar reduction in hepatic copper levels in our Sco1hrt/hrt livers, we did not observe a 
concordant increase in serum copper levels or ATP7A abundance. CCS levels in the Sco1 knockout 
and knock-in hearts were also unchanged. We therefore believe that unlike the Ctr1 knockout heart, 
hearts of our Sco1 transgenic models are incorrectly signalling a state of copper excess to the livers 
which in turn results in CTR1 degradation.  
It is tempting to assume that the changes in CTR1 observed with perturbations in Sco1 
expression are a direct reflection of the isolated COX deficiency. All of our mouse models exhibited 
severe, combined copper and COX deficiencies, and affected tissues from many patients with 
pathogenic mutations in COX assembly factors including hearts from SURF1 patients (Stiburek et al., 
2009) and fibroblasts from both COX10 and COX15 patients (Leary et al., 2007) are also severely 
copper deficient; however, multiple lines of evidence argue against the COX deficiency being the 
primary driver of the copper deficient state in either organism. Overexpression of SCO2 in both SCO1 
and COX15 patient fibroblasts functionally complements the copper deficiency without affecting an 
increase in residual COX activity (Leary et al, 2007). Rho0 cells, which lack mitochondrial DNA and 
therefore are unable to assemble COX, only have a modest reduction in CTR1 levels. Finally, while 
Cox10 and Lrpprc knockout livers exhibit COX and copper deficiencies of comparable severity, 
CTR1 abundance was markedly reduced in the Cox10 knockout liver while ATP7A levels were 
significantly increased in the Lrpprc knockout liver in the absence of changes in CTR1. These 
observations collectively suggest that inputs other than the COX deficiency contribute critically to the 
transduction of signals that target the import or the export machinery in fundamentally different ways. 
If the COX deficiency is not the primary cause of the copper deficiency than what is the nature 
of the signal that is released from the mitochondrion that regulates CTR1 function? One intriguing 
possibility is the contribution of oxidative biology to modulating the activity of this signalling 
pathway. The mitochondrial matrix is a relatively oxidizing environment, with the ratio of reduced to 
oxidized glutathione (GSH:GSSG) being significantly lower than that of the cytosol (Shen et al., 
2005). The import of many proteins within the IMS relies on their oxidative folding, which involves 
the systematic oxidation of cysteinyl sulphur pairs through the MIA40-ERV1 disulphide relay 
(Mesecke et al., 2005). Mitochondria are also capable of generating reactive oxygen species through 
the electron transport chain. Therefore, reducing and oxidizing inputs offer a convenient means of 
regulating the generation and transduction of mitochondrial signals that ultimately affect CTR1 
function. Post-translational modifications that result in the sulfenylation, glutathionylation or 
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nitrosylation of cysteinyl sulphurs in fact exert profound effects on protein function (Kim et al., 2002). 
It is thus possible that redox regulation of the cysteinyl sulphurs within the Cx3C motif of SCO1, or 
other cysteine-containing proteins known to interact with SCO1 within the IMS, directly contributes 
to modulating the activity of an organellar copper signalling pathway. Tissue-specific differences in 
the abundance of key players that orchestrate these reversible post-translational modifications may 
provide for relative enrichment for a particular redox species that in turn results in cell-type specific 
regulation of CTR1 function. However, it is just as likely that distinct, tissue-specific changes in CTR1 
localization and/or abundance in response to loss of SCO1 function are mediated by unique effectors 
that are downstream of the initial copper sensing signal.  
Although glutathione (GSH) is essential to maintaining redox balance, it also has a critical role 
in maintaining cellular copper homeostasis. GSH can bind copper and plays a critical role in protecting 
the cell during copper overload (Freedman et al., 1989). It is also required for CTR1 dependent copper 
import into the cell (Maryon et al., 2013b), as it binds the imported copper and passes the metal ion 
down an affinity gradient to metallochaperones like CCS and ATOX1 (Banci et al., 2010). 
Glutathionylation of ATOX1, ATP7A and ATP7B strongly inhibits the function of these proteins and 
as a result cellular copper efflux (Singleton et al., 2010). As such, it may be that GSH plays a similar 
role in copper signalling within the mitochondrion. The mitochondrial matrix contains 10-15% of the 
cellular GSH pool, presumably due to the oxidative nature of the organelle (Marí et al., 2009). 
Mitochondrial GSH acts as a buffer against deleterious side reactions driven by reactive oxygen 
species, yet mutations in ATP7A increase mitochondrial copper levels and disrupt redox balance 
within the organelle by saturating this buffering capacity (Bhattacharjee et al., 2016). It may be that 
alterations in mitochondrial copper cause changes within the redox state of the organelle and that this 
in turn is communicated to the rest of the cell in a SCO1-dependent manner through the regulation of 
its cysteinyl sulphurs. However, this possibility remains untested experimentally and warrants further 
investigations. 
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6. Conclusions 
The work presented within this thesis has furthered the idea that the inner mitochondrial 
membrane protein SCO1 has an essential role in maintaining cellular copper homeostasis. Proving 
our hypothesis, we have shown that mice lacking SCO1 in both the liver and heart phenocopy SCO1 
patients and display a significant isolated COX deficiency as well as a severe copper deficiency. 
Contrary to the copper deficiency observed in human SCO1 patients, the copper deficiency in our 
mouse models was caused by defects in the high-affinity copper import pathway, albeit by different 
mechanisms in different tissues (Figure 6.1). Livers lacking Sco1 expression exhibited internalization 
and degradation of CTR1, whereas in hearts lacking Sco1, CTR1 abundance was maintained but the 
protein was mislocalized and maintained on endosomes. The exact cause and the proteins or genes 
responsible for these tissue-specific differences are unknown. 
One of the main limitations in studying human disease states with knockout mouse models is 
that the absence of protein is not equivalent to the expression of a partially functional mutated protein. 
To mitigate this issue, we developed a knock-in mouse model with global expression of G115S Sco1 
pathogenic variant, analogous to the human G132S mutation that is known to cause hypertrophic 
cardiomyopathy. Examining the hearts of these mice, we found a similar phenotype to that of our 
heart specific knockout mice, with a severe copper deficiency and a mislocalization of CTR1 within 
the cardiac tissue. The fact that our knockout model so closely phenocopied the knock-in model 
analogous to the human condition provides support that these models are viable to studying SCO1 
human patients. 
Finally, data presented within this thesis demonstrates that the deletion of SCO1 in the heart 
activated a systemic copper signalling pathway which resulted in a copper deficiency in the liver. This 
further establishes the existence of such a copper signalling pathway between the heart and liver, 
however, we observed minor differences compared to the previously reported pathway. The hepatic 
copper deficiency in the heart-specific SCO1 was caused by a decrease in the abundance of CTR1, 
compared to an increase in ATP7A expression observed in the livers of heart-specific CTR1 knockout 
mice. These differences perhaps suggest that our model represents the signalling of copper overload 
rather than copper deficiency. 
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Figure 6.1: Deletion of Sco1 causes changes in CTR1 localization and abundance 
Wild-type SCO1 (left) maintains proper expression of CTR1 with the protein primarily being 
localized to the plasma membrane but being in dynamic equilibrium with the cytosol. Deletion of 
Sco1 in the liver (middle) results in CTR1 being internalized from the plasma membrane and degraded 
via the proteasome. Deletion of Sco1 in the cardiomyocytes (right) results in mislocalization of the 
protein from the intercalated discs onto endosomes while maintaining wild-type abundance of the 
protein. 
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7. Future Directions 
We have shown that SCO1 has an essential role in maintaining both the localization and 
abundance of CTR1 in multiple tissues; however, this raises multiple questions with regards to how 
this system functions. Primarily, how does SCO1, a protein tethered to the inner mitochondrial 
membrane, communicate with the periphery of the cell to regulate the localization CTR1? It may be 
that SCO1 communicates though the use of a soluble secondary messenger with dual localization 
between the mitochondria and cytosol, analogous to the role COX19 plays in regulating copper efflux 
in the human SCO1 patient fibroblasts (Leary et al., 2013b). However, a liver-specific COX19 
knockout mouse has a significant hepatic copper deficiency (Leary lab unpublished data), suggesting 
that COX19 can not be the sole protein involved in emanating a signal from the mitochondria. 
Therefore, future work must be completed to determine the downstream proteins that are involved in 
transmitting the copper signal. Certainly, establishing primary tissue culture models from the Sco1 
knockout mice would aid in answering this question. Assuming such a model could be generated and 
validated to function the same as the knockout tissues, knockdown experiments could be performed 
to reduce the abundance of soluble proteins known to have dual localization between the mitochondria 
and cytosol to examine the role these proteins having in communicating mitochondrial copper signals. 
Primary tissue culture models lacking Sco1 would also aid in determining the tissue specific 
differences resulting in CTR1 being degraded in the liver but not in the heart, another question raised 
by the data in this thesis. Pull-down experiments in the hearts and livers of wild-type and Sco1 tissue-
specific knockout mice could determine potential interactors with CTR1 that may be targeting the 
protein for internalization or degradation, such as proteins involved in specific endocytic pathways or 
protein specific E3 ubiquitin ligases. If a list of potential proteins could be identified within the Sco1 
knockout tissues, these proteins could be knocked down in the primary cell models to determine if 
they are essential in maintaining the proper localization and abundance of CTR1.  
The data presented within this thesis suggests that SCO1 may sit at the head of the copper 
sensing and signalling pathway; however, copper deficiencies were observed in all mouse models 
examined with isolated COX deficiencies. It may be that a separate process senses alterations of 
copper levels in the cell, e.g. the redox state of the mitochondrion, and this process acts through SCO1 
to regulate cellular copper levels. The mitochondrial redox state is an intriguing possibility for this 
function as it is perturbed by genetic manipulations that cause copper overload (Bhattacharjee et al., 
2016). Fittingly, it has also been shown that the redox state of the cysteinyl sulphurs of SCO1 change 
under copper replete or deficient conditions (Leary et al., 2013b). Experiments could be performed to 
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examine the redox state of the organelle upon deletion or perturbation of SCO1 function to determine 
if it is altered in a similar manner to cells under copper excess conditions, which would provide further 
evidence in support of our hypothesis that SCO1 perturbed cells are incorrectly signalling a copper 
overload. 
The overexpression of SCO2 rescuing the copper deficiency in the SCO1 patient fibroblasts 
suggests that redox state of the mitochondria or at the very least SCO1 is central to the copper 
signalling mechanism (Leary et al., 2007). Further investigation should be performed into the role of 
SCO2 in these copper signalling pathways within the tissues of our knockout mice. Why is it that the 
overexpression of SCO2 results in the rescue of the copper phenotype while causing a dominant 
negative COX phenotype? Would over-expression of SCO2 in our knockout mouse or tissue culture 
models rescue copper levels in a similar fashion? Can we manipulate the redox state of these proteins 
without manipulating SCO2 abundance, e.g. by using antioxidants, and will that affect the levels of 
copper or CCS within the cell, possibly signalling a copper overload or deficient state?  
Despite our validation and basic characterization of hearts of the G115S knock-in mouse, work 
remains to determine the cause of the tissue specific differences observed in human SCO1 patients. 
Generation and characterization of knock-in mice harbouring the other human pathogenic Sco1 alleles 
will be essential to answering these questions; however, this is made more difficult given that the 
P174L and M294V human pedigrees are both compound heterozygotes, necessitating the mice 
harbour both one knock-in and one deleted allele. Will expression of the other pathogenic alleles at 
appropriate levels result in a similar tissue specific phenotype in the mice? Will there be differences 
in the levels of COX activity or copper concentrations in the tissues of the mice expressing different 
pathogenic variants? If these differences do exist it may indicate why we see such stark differences in 
the human disease states.  
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